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Abstracts
Abstracts presented at the Fourth International Synovitis Workshop
Dallas, Texas, 21–25 April 1999
Peter E Lipsky (Organizer), Simmons Arthritis Research Center
Genetics of Rheumatoid Arthritis
Gerald T Nepom
Virginia Mason Research Center, Seattle, Washington, USA
Genetic associations between rheumatoid arthritis and specific
HLA class II genes provide clues to understanding the
molecular basis for disease susceptibility. There is a remarkable
structural relationship among different rheumatoid arthritis (RA)
susceptibility genes, in which each of the associated class II
alleles encodes a sequence of key amino acids termed the
‘shared epitope.’ Mechanistic models to account for the shared
epitope association with RA can be interpreted in the context of
an HLA-directed pathway for the development of disease. We
suggest that altered T cell activation results from recognition of
the shared epitope, providing a potential mechanism by which
the shared epitope may be involved in the generation or
modulation of self-recognition during antigen presentation and
processing. We propose that the shared epitope association
with RA is not solely based on a specific peptide binding motif
and peptide determinant selection but rather is influenced by a
strongly biased direct recognition of shared epitope residues by
direct T cell contact.
1. Nepom GT: Major histocompatibility complex-directed susceptibil-
ity to rheumatoid arthritis. Adv Immunol 1998, 68: 315–332.
Immunogenetic Aspects of Disease Progression in
Rheumatoid Arthritis
Ralf Wassmuth MD1, Sylke Kaltenhäuser MD2, Ulf Wagner
MD2, Sybille Arnold MD2, Wolfram Seidel MD2, Michael
Tröltsch MD2, Ernst Schuster MD3, Markus Löffler PhD3,
Joachim R. Kalden MD1, Holm Häntzschel, MD2
1University of Erlangen-Nürnberg, Erlangen, Germany,
2University of Leipzig, Leipzig, Germany, 3Institute for Medical
Informatics, Statistics and Epidemiology, University of Leipzig,
Leipzig, Germany
In an ongoing collaborative prospective study aimed at the
identification of prognostic factors for the development of
erosive disease and clinical severity of disease in early
rheumatoid arthritis (RA) [1], 48 patients were followed for more
than 4 years, and 87 patients were seen for 2 years. Significant
associations with progressive joint destruction, measured by the
Larsen index, were observed after 2 and 4 years for three
parameters: 1) the presence of rheumatoid factor IgM; 2) bony
erosions present at study entry, and 3) HLA DRB1 markers.
Patients who expressed the shared epitope on a DR4 allele had
significantly higher Larsen indices after 2 years (0.86 vs 0.12;
P=0.0015) and after 4 years (1.22 vs 0.53; P=0.002) of
disease duration. Similarly, the presence of the epitope
sequence on either DR1 or DR4 also resulted in higher Larsen
indices for epitope-positive patients (0.59 vs 0.06; P=0.006
after 2 years, and 1.0 vs 0.69; P=0.03 after 4 years). A more
severe radiologic outcome after 2 years (Larsen index >0.7)
was detected with a sensitivity of 0.7, 0.61, and 0.58 and a
specificity of 0.42, 0.84 and 0.75 using RF IgM, erosiveness at
initial presentation, and presence of the shared epitope on a
DR4 as prognostic parameters. Most useful, however, was the
combination of DR4 positivity and erosiveness at study entry as
prognostic indicators of a more severe course of joint
destruction (sensitivity 0.68; specificity 0.77).
In summary, seropositivity, early erosiveness, and RA-
associated HLA-DRB1 markers are useful prognostic
indicators of the progression of joint destruction. Moreover, this
influence is sustained during the first four years of the course of
the disease.
1. Wagner U, Kaltenhauser S, Sauer H, et al: HLA markers and predic-
tion of clinical course and outcome in rheumatoid arthritis. Arthritis
Rheum 1997, 40:341–351.
Rheumatoid Arthritis: A Polygenic Disease with Multiple
Phenotypes
Cornelia M Weyand
Mayo Clinic, Rochester, New York, USA
Rheumatoid arthritis (RA) is recognized as a multigene disorder
with a number of genetic polymorphisms contributing to
disease pathogenesis. Here, we propose that the diagnostic
category of RA includes multiple subtypes of disease and that
the different phenotypes of RA correlate to different genotypes.
Genetics of Rheumatoid Arthritis
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Support for this concept has come from a reappraisal of the
clinical heterogeneity of RA and the observation that HLA-
DRB1 polymorphisms are useful in describing genetic
heterogeneity of RA phenotypes. A series of HLA-DRB1 genes
has been identified as RA-associated and, in recent years,
emphasis has been put on the sequence similarities of these
alleles. An alternative view focuses on the amino acid variations
found with different alleles being enriched in distinct subtypes
of RA. Rheumatoid factor positive destructive joint disease is
predominantly associated with the HLA-DRB1*0401 allele
while HLA-DRB1*0404 and B1*0101 predisposes for milder
and often seronegative disease. Expression of disease-
associated alleles on both haplotypes carries a high risk for
extra-articular manifestations. Besides HLA gene
polymorphisms, emergence of CD28-deficient CD4 T cells
identifies RA patients with extra-articular manifestations. These
cells undergo clonal expansion in vivo, produce high amounts
of IFN-g and exhibit autoreactivity. Concordance of
monozygotic twins for the expression of CD4+CD28- T cells
suggests a role for genetic factors in the generation of these
unusual T cells. Evidence for heterogeneity of the synovial
component of RA comes from studies describing three distinct
patterns of lymphoid organizations in the synovium. Each
pattern of lymphoid organization correlates with a unique profile
of tissue cytokines, demonstrating that several pathways of
immune deviation modulate disease expression in RA. Defining
RA variants has major implications on how the disease is
studied, treated, and managed. Identifying combinations of RA
risk genes that correlate with disease variants could become
an important diagnostic tool.
1. Weyand CM, Hicok KC, Conn DL, Goronzy JJ: The influence of HLA-
DRB1 genes on disease severity in rheumatoid arthritis. Ann
Intern Med 1992, 117:801–806.
2. Weyand CM, McCarthy TG, Goronzy JJ: Correlation between
disease phenotype and genetic heterogeneity in rheumatoid
arthritis. J Clin Invest 1995, 95:2120–2126.
3. Klimiuk PA, Goronzy JJ, Björnsson J, Beckenbaugh RD, Weyand CM:
Tissue cytokine patterns distinguish variants of rheumatoid syn-
ovitis. Am J Pathol 1997, 151:1311–1319.
4. Martens PB, Goronzy JJ, Schaid D, Weyand CM: Expansion of
Unusual CD4+ T Cells in Severe Rheumatoid Arthritis. Arthritis
Rheum 1997, 40:1106–1114.
5. Weyand CM, Goronzy JJ: Pathogenesis of rheumatoid arthritis.
Med Clin North Amer 1997, 81:29–55.
6. Weyand CM, Klimiuk PA, Goronzy JJ: Heterogeneity of rheumatoid
arthritis: from phenotypes to genotypes. Springer Semin
Immunopathol 1998,  20:5–22.
7. Weyand CM, Schmidt D, Wagner U, Goronzy JJ: The influence of
sex on the phenotype of rheumatoid arthritis. Arthritis Rheum
1998,  41:817–822.
T Cells in Rheumatoid Arthritis
Redox Balance Alterations and Hyporesponsiveness of
Synovial T Cells in Rheumatoid Arthritis
Ferdinand C Breedveld, SI Gringhuis, MM Maurice,
CL Verweij
Leiden, The Netherlands
In rheumatoid arthritis (RA), the functional status of T
lymphocytes is incompletely understood. Synovial fluid (SF) T
lymphocytes display phenotypic evidence of former activation,
but there is hardly any production of T cell derived cytokines in
the synovium. Moreover, the in vitro proliferative responsiveness
of SF T lymphocytes is decreased compared with that of
peripheral blood (PB) T lymphocytes.
Previous studies have revealed reduced intracellular Ca²+
responses and a decreased overall tyrosine phosphorylation
pattern in SF T lymphocytes upon TCR/CD3 simulation [1].
Specifically, the tyrosine phosphorylation of the TCR zeta
chain, one of the most proximal events in TCR signaling, was
clearly diminished in RA SF T lymphocytes [2]. Moreover, the
phosphorylation of a 36kDa protein was virtually absent in RA
SF T lymphocytes. Here we report that the 36kDa protein is
identified as LAT (linker for activation of T cells). In healthy T
lymphocytes, LAT is heavily phosphorylated on tyrosine
residues by ZAP-70 (zeta-associated protein of 70kDa) upon
TCR engagement, which is required for the activation of
PLCg1 and the subsequent influx of Ca²+ [3]. Using FACS
analysis, we show that the expression of LAT is reduced in both
SF and PB T lymphocytes from RA patients compared with T
lymphocytes from healthy controls.
LAT is normally a membrane-bound protein due to the
presence of a short a-helical structure. Using immuno-
fluorescence staining and microscopy, we found that LAT is
displaced from the membrane in SF but not PB T
lymphocytes from RA patients. The synovium provides an
environment of oxidative stress for the SF T lymphocytes,
which are severely depleted in their intracellular levels of the
antioxidant glutathione (GSH). The replenishment of GSH in
SF T lymphocytes by treatment with NAC (N-acetyl-L-
cysteine) restores the membrane localization of LAT, and also
the phosphorylation of LAT and the expression of IL-2 after
TCR stimulation.
Conclusively, it is demonstrated that the hyporesponsiveness
of synovial T lymphocytes in RA is associated with the
membrane-displacement of LAT. The membrane localization of
LAT is sensitive to intracellular GSH alterations [4]. The
displacement of LAT fails to bring ZAP-70 in its proximity after
TCR stimulation, whereby LAT remains unphosphorylated and
the TCR-mediated signaling pathway is abrogated. Hence,
these results suggest a role for the membrane-displacement of
LAT in the hyporesponsiveness of SF T lymphocytes as a
consequence of local oxidative stress.3
1. Mirza NM, Relias V, Yunis EJ, Pachas WN, Dasgupta JD: Defective
signal transduction via T-cell receptor CD3 structure in T cells
from rheumatoid arthritis patients. Hum Immunol 1993, 36:91–98.
2. Maurice MM, Lankester AC, Bezemer AC et al: Defective TCR-medi-
ated signaling in synovial T cells in rheumatoid arthritis. J Immunol
1997, 159:2973–2978.
3. Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE: LAT:
the ZAP-70 tyrosine kinase substrate that links T cell receptor to
cellular activation. Cell 1998, 92:83–92.
4. Maurice MM, Nakamura H, van der Voort EAM et al: Evidence for the
role of an altered redox state in hyporesponsiveness of synovial T
cells in rheumatoid arthritis. J Immunol 1997, 158:1458–1465.
T Cell Homeostasis and Repertoire Contraction in
Rheumatoid Arthritis
Jörg J. Goronzy
Mayo Clinic, Rochester, New York, USA
Rheumatoid arthritis (RA) is not limited to chronic articular
inflammation, but patients have alterations in their global
immune system in line with the clinical experience of significant
systemic disease. Specifically, RA patients frequently have
clonal T cell populations in the circulation that characteristically
lack the expression of the CD28 molecule. Here, we propose
that RA patients have a defect in T cell generation that results
in the contraction of the T cell repertoire and eventually in the
emergence of CD28null clonal T cells. We have determined the
diversity of the peripheral CD4 T cell repertoire by determining
the frequencies of arbitrarily selected T cell receptor (TCR) b-
chain sequences. Healthy individuals displayed a highly diverse
repertoire, with a median frequency of individual TCR b-chain
sequences of 1 in 2.4×107 CD4 T cells. In RA patients, the
median TCR b-chain frequency was 10-fold increased. The
loss in TCR diversity was not limited to CD4 memory T cells
but also involved naive T cells, suggesting an abnormality in T
cell repertoire formation and not a consequence of antigen
recognition in the synovium. Also, control patients with chronic
inflammatory disease such as hepatitis C expressed a diverse
repertoire. In further support for this concept, telomere length
studies indicated an increased replicative history of peripheral
CD4 T cells in RA patients. Lymphocyte telomeres were age-
inappropriately shortened with almost complete telomere
erosion at an age of less than 40 years. Again, naive T cells
were predominantly affected, and their capacity to undergo
clonal burst after stimulation was about 10-fold reduced. These
data are consistent with a premature exhaustion of
lymphopoiesis in RA that may contribute to the autoimmune
response as well as to the immunodeficiency in these patients
and has important implications for their clinical management.
1. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ: Emer-
gence of oligoclonal T cell populations following therapeutic T cell
depletion in rheumatoid arthritis. Arthritis Rheum 1995, 38:-
1242–1251.
2. Schmidt D, Goronzy JJ, Weyand CM: CD4+ CD7- CD28- T cells are
expanded in rheumatoid arthritis and are characterized by autore-
activity. J Clin Invest 1996, 97:2027–2037.
3. Wagner UG, Koetz K, Weyand CM, Goronzy JJ: Perturbation of the T
cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA
1998,  95:14447–14452.
4. Walser-Kuntz DR, Weyand CM, Weaver AJ, O’Fallon WM, Goronzy JJ:
Mechanisms underlying the formation of the T cell receptor reper-
toire in rheumatoid arthritis. Immunity 1995, 2:597–605.
5. Waase I, Kayser C, Carlson PJ, Goronzy JJ, Weyand CM: Oligoclonal
T cell proliferation in patients with rheumatoid arthritis and their
unaffected siblings. Arthritis Rheum 1996, 39:904–913.
6. Rittner HL, Zettl A, Jendro MC, Bartz-Bazzanella P, Goronzy JJ,
Weyand CM: Multiple mechanisms support oligoclonal T cell
expansion in rheumatoid synovitis. Mol Med 1997, 3:452–465.
Contribution of T Cell Subsets to Joint Degradation
Pierre Miossec
Hospital E Herriot, Lyon, France
The role of T cells in the pathogenesis of rheumatoid arthritis
(RA) has been and remains a matter of debate. One of the
arguments for discussing such contribution has been the
difficulty to measure the production of cytokines described as
characteristic of T cells such as IFNg. However, when the
technology used to raise antigen specific T cell clones was
applied to T cells from RA synovium, such cells were found to
be fully able to produce IFNg. In addition, RA synovium
immunostaining revealed the presence of IFNg producing cells.
Conversely, the production of IL-4, another T cell cytokine, was
found to be low and, to some extent, defective. Such findings
led to the classification of RA as a Th1-associated disease.
More recently, IL-17 has been described as a proinflammatory
cytokine specifically produced by T cells. Studies with
supernatants of RA synovium explants showed a high
production of bioactive IL-17. Such an effect was linked to a
synergistic interaction between IL-17 and the major monocyte-
derived cytokines IL-1 and TNFa. Similarly, staining of RA
synovium showed the presence of IL-17-producing T cells.
Extension of studies with T cell clones from RA synovium
indicated that a subset of IFNg, but not of IL-4-producing T
cells, was able to produce IL-17, allowing the classification of
IL-17 as a Th1 cytokine.
The addition of blocking anti-IL-17 antibody to culture
supernatants was able to reduce by approximately 50% the
production of IL-6 LIF as well as that of MMP-1. Such an
effect resulted in an important decrease of extracellular
matrix destruction when IL-17 was inhibited. Conversely,
when the anti-inflammatory cytokines IL-4, IL-13, and, to a
lesser extent, IL-10 were added, production of
proinflammatory cytokines was inhibited, including that of IL-
17. Similarly, this resulted in an increase of TIMP production
associated with reduced destruction. In the same conditions,
increased repair as indicated by collagen synthesis was
observed.
Through their production of cytokines, a subset of Th1 T
cells can aggravate the proinflammatory and destructive
pattern associated with monocyte activation. Manipulation of
the cytokine profile of such a subset may control the
destructive pattern, which remains a therapeutic target
difficult to control.
http://arthritis-research.com/supplements/1/S11. Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Waldez H,
Banchereau J: Inhibition of the production of proinflammatory
cytokines and immunoglobulins by Interleukin 4 in an ex vivo
model of rheumatoid synovitis. Arthritis Rheum 1992, 35:874–883.
2. Quayle AJ, Chomarat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig
JB: Rheumatoid inflammtory T cell clones express mostly TH1, but
also TH2 and mixed (TH0-like) cytokine patterns. Scand J Immunol
1993, 38:75–82.
3. Miossec P, van den Berg W: The Th1/Th2 cytokine balance in
arthritis. Arthritis Rheum 1997, 40:2105–2115.
4. Miossec P, van den Berg W, Firestein G: T cells in arthritis. Basel:
Birkhauser; 1998.
5. Chabaud M, Durand JM, Fossiez F, Frappard L, Miossec P: IL-17, a T
cell derived proinflammatory cytokine produced by the rheuma-
toid synovium. Arthritis Rheum 1999, 42:963–970.
6. Aavak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by
some proinflammatory Th1/Th0 cells but not by Th2 cells. J
Immunol 1999, 162:1246–1251.
The p78 Putative Rheumatoid Arthritis T Cell Autoantigen
GS Panayi, M Bodman-Smith, M Fife, V Corrigall,
D Pappin* and J Lanchbury
Guy’s, King’s, and St. Thomas’ School of Medicine, King’s
College, Guy’s Hospital, and *Imperial Cancer Research
Fund, London, United Kingdom
Abstract not available
Altered T Cell Differentiation in Patients with Early
Rheumatoid Arthritis
Alla Skapenko, Jörg Wendler, Peter E Lipsky, Joachim R
Kalden, and Hendrik Schulze-Koops
University of Erlangen-Nuremberg, Erlangen, Germany and
University of Texas Southwestern Medical Center, Dallas,
Texas, USA
Chronic inflammation in rheumatoid arthritis (RA) is likely to
be driven by activated Th1 cells without sufficient Th2 cell
differentiation to down-modulate inflammation [1,2]. To test
whether, in RA, Th cells express an alteration in their ability
to differentiate into effector cells, we investigated Th cell
differentiation in patients with early untreated RA and in age-
and sex-matched controls in vitro. All patients had active RA
with symptoms of the disease for 6 weeks to 12 months. A
cell culture system was used that permitted the
differentiation of Th effectors from resting memory T cells by
short-term priming [3]. No difference in the cytokine
secretion profile of freshly isolated T cells was detected
between patients and controls. However, marked differences
were found in the response to priming. Th2 cells could be
induced in all healthy individuals by priming with anti-CD28
in the absence of TCR ligation. By contrast, priming under
those conditions resulted in Th2 differentiation in only 9/24
RA patients. The addition of exogenous IL-4 could overcome
the apparent Th2 differentiation defect in seven patients but
was without effect in the remaining eight patients. In all
patients, a marked decrease in IL-2 producing cells and a
significant increase in well-differentiated Th1 cells that
produced IFN-g but no IL-2 was evident after priming with
anti-CD3 and anti-CD28 [4]. The data suggest that CD4+
memory T cells from patients with early untreated RA
manifest an intrinsic abnormality in their ability to differentiate
into specific cytokine producing effector cells, which might
contribute to the characteristic Th1 dominated chronic
(auto)immune inflammation in RA.
1. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1-
or Th0-like cytokine mRNA in peripheral circulation of patients
with rheumatoid arthritis: modulation by treatment with Anti-
ICAM-1 correlates with clinical benefit. J Immunol 1995,
155:5029–5037.
2. Simon AK, Seipelt E, Sieper J: Divergent T-cell cytokine patterns in
inflammatory arthritis. Proc Natl Acad Sci USA 1994,
91:8562–8566.
3. Schulze-Koops H, Lipsky PE, Davis LS: Human memory T cell differ-
entiation into Th2-like effector cells is dependent on IL-4 and
CD28 stimulation and inhibited by TCR ligation. Eur J Immunol
1998,  28:2517–2529.
4. Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H:
Altered memory T cell differentiation in patients with early
rheumatoid arthritis. J Immunol 1999, 163:491–499.
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B Cells in Rheumatoid Arthritis
Evidence for an antigen-driven immune response in the
chronically inflamed synovium
Claudia Berek and H-J Kim
Deutsches Rheuma ForschungsZentrum, Berlin, Germany
Recently it has been shown that proinflammatory cytokines, like
TNF-alpha and lymphotoxin play a crucial role in the
organogenesis of the lymphoid tissue. Thus, during chronic
inflammation, in the affected tissue, these cytokines may
promote the development of a micro-environment which
supports a local immune response. In patients with rheumatoid
arthritis large lymphocytic infiltrates are often seen in the
synovial tissue. These cell clusters have a characteristic
arrangement of T, B and plasma cells. Proliferating B cells are
found only centrally in a network of follicular dendritic cells.
Using micro-manipulation CD20+ B cells and plasma cells
were isolated separately from different parts of single infiltrates.
DNA was extracted and the VH/VL gene repertoires
determined. The data show that within the network of follicular
dendritic cells there is an oligoclonal expansion of B cells.
During proliferation V-gene variants are generated by the
hypermutation mechanism. The pattern of somatic mutations
suggests that both naive and memory B cells become activated
in the synovial tissue. Within single infiltrates we did not findidentical rearrangements between CD20+ B and plasma cells.
Nevertheless, the finding of clonally related plasma cells
suggests that these cells underwent terminal differentiation in
the synovial tissue. The analysis of individual B cells recovered
from synovial tissue opens a new way to determine the
specificity of those cells which take part in the local immune
reaction.
1. Berek C, Kim H-J: B-cell activation and development within chroni-
cally inflamed synovium in rheumatoid and reactive arthritis. Sem
Immunol 1997, 9:261–268.
2. Fu Y-X, Chaplin DD: Development and maturation of secondary
lymphoid organs. Annu Rev Immunol 1999, 17:399-433.
3. Kim H-J, Krenn V, Steinhauser G, Berek C: Plasma cell development
in synovial germinal centers in patients with rheumatoid and reac-
tive arthritis. J Immunol 1999, 162:3053–3062.
4. Randen I, Mellbye J, Forre O, Natvig JB: The identification of germi-
nal centres and follicular dendritic networks in rheumatoid syn-
ovial tissue. Scand J Immuol 1995, 41:481–486.
5. Schröder AE, Greiner A, Seyfert C Berek C: Differentiation of B cells
in the nonlymphoid tissue of the synovial membrane of patients
with rheumatoid arthritis. Proc Natl Acad Sci USA 1996, 93:
221–225.
Expression of RAG1, RAG2, and TdT in Rheumatoid
Arthritis Synovia: Evidence for Receptor Revision of
Immunoglobulin Light Chains
S Louis Bridges Jr and Zhixin Zhang
University of Alabama at Birmingham and Birmingham VA
Medical Center, USA
Some rheumatoid arthritis (RA) synovia contain structures
similar to germinal centers (GC), the site of affinity maturation
of B lymphocytes [1,2]. Previous analyses of immunoglobulin
(Ig) kappa and lambda light chains expressed in RA synovia
showed clonally related sequences with frequent N region
addition and unusually long CDR3s [3,4]. The presence of
clonally related Ig heavy chain sequences in GC-like
structures from RA synovia suggests in situ antigen-
dependent B cell maturation. RAG1 and 2, enzymes that
mediate V(D)J recombination during B cell development, are
expressed in a subset of GC B cells in normal peripheral
lymphoid organs [5,6]. RAG expression allows secondary Ig
rearrangements, which salvages B cells with undesirable
specificities or low antigen affinity (receptor revision). We
sought to determine whether RAG and TdT (the enzyme
responsible for N region addition) are expressed in RA synovia
and whether secondary Ig rearrangements occur. Using
nested RT-PCR, we detected RAG1, RAG2, and TdT mRNA
in 8, 9, and 6 of 12 synovial samples (11 RA, 1 JRA),
respectively. RAG1 was expressed in B cells (5/8 samples)
and T cells (4/8). RAG2 was expressed in B cells (4/8) more
often than in T cells (1/8). TdT was expressed in B cells only
(2/8). Immunohistochemical staining indicated that RAG
proteins were distributed in lymphoid aggregates. In some
synovia, secondary rearrangement products (ds-DNA breaks
at recombination signal sequences in the Jkappa region) were
detected by ligation-mediated PCR. We speculate that
receptor revision in nonlymphoid tissues such as RA synovia
may generate autoreactive antibodies, which has important
implications for chronic inflammatory diseases.
1. Randen I, Mellbye OJ, Førre O, Natvig JB: The identification of ger-
minal centres and follicular dendritic networks in rheumatoid syn-
ovial tissue. Scand J Immunol 1995, 41:481–486.
2. Schröder AE, Greiner A, Seyfert C, Berek C: Differentiation of B
cells in the nonlymphoid tissue of the synovial membrane of
patients with rheumatoid arthritis. Proc Natl Acad Sci, USA.1996,
93:221–225.
3. Bridges SL, Jr: Frequent N addition and clonal relatedness among
immunoglobulin lambda light chains expressed in rheumatoid
arthritis synovia and PBL, and the influence of Vlambda gene
segment utilization on CDR3 length. Molecular Med 1998,
4:525–553.
4. Bridges SL, Jr, Lee SK, Johnson MJ, et al: Somatic mutation and
CDR3 lengths of immunoglobulin kappa light chains expressed in
patients with rheumatoid arthritis and normal individuals. J Clin
Invest 1995, 96:831–841.
5. Papavasiliou F, Casellas R, Suh H, et al: V(D)J recombination in
mature B cells: a mechanism for altering antibody responses.
Science 1997,  278:298–301.
6. Han S, Zheng B, Schatz DG, Spanopoulou E, Kelsoe G: Neoteny in
lymphocytes: Rag1 and Rag2 expression in germinal center B
cells. Science  1996,  274:2094–2097.
Role of Rheumatoid Factor B Cells in Normal and
Pathologic Antigen Presentation
Dennis A Carson
University of California at San Diego Medical School, San
Diego, California, USA
The pathogenesis of rheumatoid arthritis (RA) is a major focus
of my research group. We have used molecular and
immunologic techniques to attack three main problems: 1) the
role of anti-lgG autoantibodies (rheumatoid factors) in normal
immune responses to environmental antigens, and in RA, 2) the
mechanism by which HLA-DR4 contributes to the pathogenesis
of RA, and 3) the role of the synovial microenvironment in RA.
The results of our investigations have shown that genes
encoding rheumatoid factor autoantibodies are present in the
germ line of most people. Their immunoglobulin products
greatly potentiate the presentation of tiny amounts of antigen
during secondary immune responses, and also may provide
bystander help for T cell activation. The development of high-
affinity pathogenic lgG rheumatoid factors is normally
prevented by an antigen-specific deletion mechanism. This
mechanism fails in RA.
HLA-DR4 molecules contain a short peptide sequence, ‘the
shared epitope,’ that is duplicated in the dnaJ class of heat
shock proteins in bacteria and in the gp 120 capsid protein of
EBV. Patients with early RA, but not normal subjects, have
circulating Th1-type T lymphocytes that respond to these
exogenous antigens but not to autologous HLA-DR4 molecules.
The synovium has a rich blood supply and macrophage lining.
Consequently, exogenous antigens easily become trapped
there. Although rheumatoid factors and HLA-DR4 molecules
normally protect the host from infection, they may promote the 5
http://arthritis-research.com/supplements/1/S1conversion of a low-grade, nonspecific synovitis into the
chronic granulation tissue characteristic of RA.
Synovial B Cells in Rheumatoid Arthritis: Clonal Expansion,
Diversification, and Persistence
Nicholas Chiorazzi and Kenji Itoh
North Shore University Hospital, Manhasset, New York, USA
The extent of B cell clonal diversity in the blood, synovial fluid
(SF) and synovial tissue (ST) of rheumatoid arthritis (RA)
patients was studied. We measured diversity using an lg VH
gene fingerprinting assay that identifies B cell clones based on
VH CDR3 length. By comparing fingerprints from genomic
(g)DNA vs cDNA, clones that were expanded in number could
be distinguished from those that were activated and contained
increased amounts of lg VH gene mRNA (but were not
necessarily numerically-expanded). These assays were
performed on total B cells and on naïve, germinal center, and
memory B cells and plasma cells. The data were confirmed by
VH gene sequence analyses.
Comparisons of the gDNA and cDNA assays indicated that
certain clones were expanded at the DNA but not at the RNA
level, suggesting increased numbers of resting memory cell-like
B cells. By contract, some clones were less expanded at the
DNA level and much expanded at the RNA level, indicating
activated B cells.
Studies of paired blood and SF or ST samples identified clones
that were joint-specific, blood-specific and blood-joint common.
When B cell clones in the SF from the same joint of the same
patient were studied over time, most of the B cell clones
changed. However, a few remained constant. The persisting
clones exhibited VH gene diversification with time. We also
compared the B cell clones present in the ST of two hip joints
surgically removed from the same RA patient at the same time.
These expanded clones also exhibited intraclonal sequence
diversity.
Finally, ST B cells were sorted into memory and plasma cell
subsets and analyzed. Certain B cell clones were unique to the
memory compartment, while others were also expressed as
plasma cells. Some of these B cell clones may play a role in the
synovitis of RA.
Can IgG Rheumatoid Factors Explain Everything?
Jo CW Edwards
University College, London, United Kingdom
The stochastic pattern of onset of rheumatoid arthritis (RA)
suggests that it is initiated not by an external stimulus but by
random genesis of new antibody species by immunoglobulin
gene mutation [1]. Most autoantibody-committed B cells
probably die from a lack of T cell help and from a follicle-centre
suicide signal from uncomplexed self antigen. IgG rheumatoid
factor (RF)-committed B cells may, in contrast, self-perpetuate,
using their antibody product both to obtain nonspecific T cell
help and, as self-associated complexes, to provide a positive
survival signal in follicle centres. They should also facilitate
survival of clones committed to production of RF of other
classes.
Molecular modelling indicates that IgG1 RF-based complexes,
comprising not more than two or three IgG molecules, should
evade complement clearance, cross endothelium, and access
tissue macrophages [2]. Recent work indicates that, of the
three IgG Fc receptors on macrophages only FcgRIIIa will
induce TNFa release in response to complexes of this size [3].
FcgRIIIa is expressed at high level only on macrophages in
tissues targeted by rheumatoid arthritis and, in dermis, only at
sites where nodules form [4]. The dominant involvement of
synovium probably reflects the sensitivity of synovial fibroblasts
to TNFa and the resulting tendency to synovial lymphoid
metaplasia with local antibody production [5].
If IgG RFs are responsible both for their own production and
for clinical disease, deletion of IgG RF-committed B cells
should produce long term-remission. Initial results from a
phase-I therapeutic trial of B cell depletion will be presented.
1. Edwards JCW, Cambridge G, Abrahams VM: Do self-perpetuating B
lymphocytes drive human autoimmune disease? Immunology
1999,  97:1868–1896.
2. Edwards JCW, Sutton BJ, Grimmett J, Abrahams VM: Rheumatoid
factor stereochemistry analysed by real space modelling. Arthritis
Rheum 1998, (suppl):S84.
3. Abrahams VM, Cambridge G, Lydyard PM, Edwards JCW: FcRIIIa
mediates tumour necrosis factor alpha secretion by human
monocytes.  Arthritis Rheum 1998, (suppl):S345.
4. Bhatia A, Blades S, Cambridge G, Edwards JCW: Differential distri-
bution of Fcg gRIIIa in normal human tissues. Immunology 1998,
94:56–63.
5. Edwards JCW, Leigh RD, Cambridge G: Expression of molecules
involved in B lymphocyte survival and differentiation by synovial
fibroblasts. Clin Exp Immunol 1997, 108:407–414.
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6Overview: Destruction of the Extracellular Matrix in
Rheumatoid Arthritis
Stephen Krane
Harvard Medical School, Boston, Massachusetts, USA
A major cause of morbidity in rheumatoid arthritis (RA) is the
destruction of the extracellular matrix (ECM) of cartilage, bone,
and soft tissues of the joint. Proteolytic enzymes, such as the
matrix metalloproteinases (MMPs) and the recently
characterized and cloned aggrecanases with disintegrin
domains, have a role in these destructive processes that result
in loss of fibrillar (collagens) and nonfibrillar components of the
ECM. MMPs, eg collagenases, cannot degrade the ECM of
mineralized bone, but mechanisms require action of specialized
cells (osteoclasts) generated from hemopoietic precursors in
marrow and in the inflammatory cell mass. Ligands, which
increase bone resorption, initiate osteoclast generation by
acting on mesenchymal cells (fibroblasts, stromal cells, and
osteoblasts) to induce cell-bound osteoclast differentiation
factor (ODF). ODF in turn binds to a receptor (RANK) on
osteoclast precursors and, with M-CSF, generates active
osteoclasts. Another factor, osteoprotegerin (OPG), binds to
ODF (also known as OPGL[ligand]) and inhibits osteoclasto-
genesis. A potent inducer of ODF is parathyroid hormone-
related peptide (PTHrP); receptors for PTH/PTHrP are found
on RA synovial fibroblasts, in culture, and by in situ
hybridization, and PTH is produced by RA synovium through
the action of inflammatory cytokines. There is evidence derived
from studies in animal models that the action of collagenase
produced by mesenchymal cells is required for PTH/PTHrP-
induced osteoclast generation. Delineation of the precise
function of the ligands and proteinases described would help in
designing therapy to prevent or retard the focal bone erosions
and more diffuse bone loss of RA.
1. Funk JL, Cordaro LA, Wei H, Benjamin JB, Yocum DE: Synovium as a
source of increased amino-terminal parathyroid hormone-related
protein expression in rheumatoid arthritis. A possible role for
locally produced parathyroid hormone-related protein in the
pathogenesis of rheumatoid arthritis. J Clin Invest 1998,
101:1362–1371.
2. Kohno H, et al: Synovial fluids from patients with osteoarthritis and
rheumatoid arthritis contain high levels of parathyroid hormone-
related peptide. J Bone Miner Res 1997, 12:847–854.
3. Kotake S, et al: IL-17 in synovial fluids from patients with rheuma-
toid arthritis is a potent stimulator or osteoclastogenesis. J Clin
Invest 1999, 103:1345–1352.
4. Yoshida T, et al: Production of parathyroid hormone-related
peptide by synovial fibroblasts in human osteoarthritis. FEBS Lett
1998, 433:331–334.
5. Krane SM, Zhao W: Collagenase in embryonic development and
postnatal remodeling of connective tissues. In Collagenases.
Edited by Hoeffler W. Austin: RG Landes Co; 1999:171–187.
6. Shima YH, et al: Osteoclast differentiation factor is a ligand for
osteoprotegerin/osteoclastogenesis-inhibitory factor and is iden-
tical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:
3597–3602.
7. Hsu H, et al: Tumor necrosis factor receptor family member RANK
mediates osteoclast differentiation and activation induced by
osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:
3540–3545.
8. Suda T, et al: Modulation of osteoclast differentiation and function
by the new members of the tumor necrosis factor receptor and
ligand families. Endocr Rev 1999, 20:345–357.
9. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem
1999, 274:21491–21494.
10. Zhao W, Byrne MH, Boyce BF, Krane SM: Bone resorption induced
by parathyroid hormone is strikingly diminished in collagenase-
resistant mutant mice. J Clin Invest 1999, 103:517-524.
11. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring
SR: Identification of cell types responsible for bone resorption in
rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol
1999, 152:943-951.
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Antigen-Presenting Cells, Macrophages, and Mast Cells in Rheumatoid Arthritis
Monocytes and Macrophages in Synovitis: Villains or
Victims?
Gerd R Burmester, Thomas Häupl, and Bruno Stuhlmüller
Department of Rheumatology, Humboldt University of Berlin,
Germany
Rheumatoid arthritis (RA) is characterized by cartilage and
bone destruction via pannus formation. It is also a systemic
disease, where monocytes are known to play an important role
in the inflammatory processes. To further investigate
mechanisms of monocyte activation, differential gene analysis
appears to be a powerful tool. Thus, we have differentially
analyzed gene expression in activated monocytes from first
(activated) and third (nonactivated) leukapheresis preparations
from an RA patient. Typical genes identified were IL-1a, IL-1b,
IL-6, and TNF-a. Furthermore, GRO-a/melanoma growth-
stimulatory activity, MIP-2/GRO-b, ferritin, a-1 antitrypsin,
lysozyme, transaldolase, EBER-1/EBER-2 associated protein,
thrombospondin-1, an angiotensin receptor-II C-terminal
homologue, RNA polymerase-III elongation factor (elongin),
three unknown (BSK-66, -80, -89), and homologues of
functionally undefined genes (BSK-67, -83) were differentially
expressed. Overexpression was confirmed for selected genes
by semiquantitative PCR analysis in monocytes from RA
patients versus healthy donors, including IL-1b, the ATR-11
homologue, BSK 66, –67 and –89. To investigate the
importance of monocytes in the synovial tissue and to take
other cells in the synovial pannus into account, especially
http://arthritis-research.com/supplements/1/S1fibroblasts, which may modulate the destructive process
essentially, a representational difference analysis has been
performed in whole synovial tissue between RA and
osteoarthritis (OA). Furthermore, a modified technique of
semiquantitative PCR was used to verify these data and to
analyze a group of genes possibly involved in the tissue
homeostasis of cartilage. A preliminary analysis of 151 clones
revealed that genes other than regulatory cytokines dominate
the difference. Especially genes of effector functions like
immunoglobulin and collagen type 1 are over-represented.
Furthermore, receptors with immunoregulatory function like
HLA-DR, natural killer cell receptor p58, and a homologue to
the cytokine receptor EB13 as well as genes involved in global
cell activity are upregulated in RA. Many clones with unknown
sequences need further investigation. Using semiquantitative
PCR, a group of genes not yet considered for RA, the bone
morphogenetic proteins (BMP), were differentially studied
between RA, OA, traumatic joint diseases, and normal tissue.
Specific members of this huge family of genes are selectively
down-regulated in synovial inflammation and possibly
differentially regulated depending on the type or stage of
inflammation.
In summary, monocytes are certainly global players in the
inflammatory process in RA. However, in the synovial tissue,
modulating factors from fibroblasts, natural killer cells, or T- and
B-cells play an essential role. Especially in chronic cartilage
degradation, the decrease of differentiation factors most likely
derived from cartilage nursing synovial fibroblasts may
contribute to joint destruction.
1. Hahn G, Stuhlmüller B, Hain N, Kalden JR, Pfizenmaier K, Burmester
GR: Modulation of monocyte activation in patients with rheuma-
toid arthritis by leukapheresis therapy. J Clin Invest 1993,
91:862–870.
2. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW: Mononuclear
phagocytes and rheumatoid synovitis. Mastermind or workhorse
in arthritis? Arthritis Rheum 1997, 40:5–18.
3. Dörffel Y, Lätsch C, Stuhlmüller B, et al: Pre-activated peripheral
blood monocytes in patients with essential hypertension. Hyper-
tension 1999, 33:in press.
4. Stuhlmüller B, Ungethüm U, Scholze S, Backhaus M, Kinne RW,
Burmester GR: Differential gene expression of activated and non-
activated monocytes from patients with rheumatoid arthritis.
1999: in press.
5. Seki T, Selby J, Häupl T, Winchester R: Use of differential subtrac-
tion method to identify genes that characterize the phenotype of
cultured rheumatoid arthritis synoviocytes. Arthritis Rheum 1998,
41:1356–1364.
6. Häupl T, Ungethüm U, Bramlage C, et al: Bone morphogenetic pro-
teins in synovial tissue from RA, OA and normal joints: implica-
tions for protective mechanisms. Arthritis Rheum 1998;
41(suppl):S195.
7. Keyszer G, Redlich A, Häupl T, et al: Differential expression of
cathepsins B and L compared with matrix metalloproteinases and
their respective inhibitors in rheumatoid arthritis and osteoarthri-
tis: a parallel investigation by semiquantitative reverse transcrip-
tase-polymerase chain reaction and immunohistochemistry.
Arthritis Rheum 1998; 41:1378–1387.
8. Ungethüm U, Häupl T, Burmester G-R: Gene products identified by
RDA subtraction in rheumatoid arthritis. J Autoimmunity 1999,
(suppl).
Dendritic Cells: What Is Their True Role in Rheumatoid
Arthritis?
R Thomas, AR Pettit, KPA Macdonald, and M Smith
Centre for Immunology and Cancer Research, Brisbane and
Repatriation Hospital, Adelaide, Australia
The use of arthroscopic biopsy for examination of rheumatoid
arthritis (RA) synovial tissue (ST) for disease activity and
prognostic indices is of major interest for improving patient
outcome and for assessing clinical trial efficacy. Dendritic cells
(DCs), the professional antigen-presenting cells of the immune
system, have been proposed to play a central role in the
initiation and perpetuation of the immune response in RA. We
have previously demonstrated that differentiated DCs can be
specifically identified in tissues by double immunohisto-
chemical staining, which includes the identification of the NFkB
family member, RelB, in the nucleus. Differentiated DCs were
thus identified in the T cell areas of normal or reactive human
lymph nodes and in a perivascular location in ST from patients
with untreated active RA. Double immunohistochemical
staining on 13 ST biopsies demonstrated that 88% of the
nRelB+ cells present are differentiated dendritic cells, the
remaining 12% comprising activated B cells, sub-lining
monocytes, and occasional follicular DCs. To examine the
relationship between the presence of differentiated DCs in the
ST and disease activity, serial ST biopsies from seven patients
with RA were obtained before and after either successful or
unsuccessful therapy, as determined by the ACR response
criteria. RA treatment-associated clinical improvement
correlated with a reduction in infiltrating differentiated DCs,
infiltrating lymphocytes, tissue vascularity, expression of TNF-a
in the lining and sub-lining layers, and CD68+ lining layer
cellularity. In contrast, IL-1b expression was not correlated.
These data suggest that clinical joint inflammation, tissue
vascularity, local TNF-a production, DC and lymphocyte
infiltration, and lining-layer hypertrophy are interdependent
events. Furthermore, taken together with published data, they
suggest that the synovial immune response and joint
destruction are linked pathogenetic processes.
1. Pettit AR, Quinn CP, MacDonald KPA, et al: Nuclear localization of
RelB is associated with effective antigen presenting cell function.
J Immunol 1997, 159:3681–3691.
2. Thomas R and CP Quinn: The functional development of dendritic
cells in rheumatoid arthritis: the role of CD86 in the synovium. J
Immunol 1996, 156:3074–3086.
3. Thomas R and PE Lipsky: Presentation of self-peptides by dendritic
cells: possible implications for the pathogenesis of rheumatoid
arthritis. Arthritis Rheum 1996, 39:183–191.
4. Thomas R, MacDonald KPA, Pettit AR, Cavanagh LL, Padmanabha J,
Zehntner S: Dendritic cells and the pathogenesis of rheumatoid
arthritis. J Leukocyte Biol 1999, 66:286–292.
5. Pettit AR, Thomas R: Dendritic cells: The driving force behind
autoimmunity in rheumatoid arthritis? Immunol Cell Biol 1999,
77:420–427.
6. Thomas R: Antigen presenting cells in rheumatoid arthritis.
Springer Semin Immunopathol 1998, 20:53–72.
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Concept
Leo BA van de Putte, PLEM van Lent, RJT Rodenburg, P
Barrera, Walther J van Venrooij, and Wim B van den Berg
University Hospital Nijmegen, The Netherlands
Rheumatoid arthritis (RA) is a chronic inflammatory disease
affecting predominantly lining structures, including synovial
tissue, tendon sheaths, bursae, pleura, and pericardium.
Characteristically, these tissues contain large numbers of
macrophages, suggesting that these cells are crucial in the
pathogenesis of the disease. Data obtained by us and by
others have indicated that phagocytic lining cells are essential
for disease onset and expression. Removal of synovial lining
cells by intra-articular injection of apoptosis-inducing
clodronate liposomes prevents joint inflammation in murine
arthritis models, and pilot data suggest that these liposomes
can be succesfully used in humans. The degree of
monocyte/macrophage (but not of T-cell) infiltration in
rheumatoid joints has been reported to correlate with both
disease activity and progression of joint destruction in
rheumatoid arthritis (RA). Recent studies have shown that
intrinsic macrophage characteristics may determine an
individual’s susceptibility to develop arthritis. Murine collagen-
induced arthritis-susceptible mouse strains were shown to
have markedly higher expression of FcK RII/III by macrophages
than nonsusceptible strains (Blom, 1999). In human RA, we
found that activated monocyte-derived macrophages produce
significantly higher IL-8 mRNA levels than those in controls,
pointing to an innate hyper-responsiveness of these cells in this
disease. The central role of lining macrophages in the
pathogenesis of RA has therapeutic consequences in terms of
targeting these cells and/or their proinflammatory products.
1. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anti-
cytokine treatment of established type II collagen-induced arthri-
tis in DBA/1 mice: a comparative study using anti-TNFI,
anti-IL-1I/b b, and IL-1ra. Arthritis Rheum 1996, 39:797–809.
2. Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM,
Goldman M, van den Berg WB: Role of IL-4 and IL-10 in murine col-
lagen-induced arthritis: Protective effect of IL-4 and IL-10 treat-
ment on cartilage destruction. Arthritis Rheum 1997, 40:249–260.
3. Kuiper S, Joosten LAB, Bendele AM, et al: Different roles of TNFI
and IL-1 in murine streptococcal cell wall arthritis. Cytokine 1998,
10:690–702.
4. Van Meurs JBJ, van Lent PLEM, Singer II, Bayne EK, van de Loo FAJ,
van den Berg WB: IL-1ra prevents expression of the metallopro-
teinase-generated neoepitope VDIPEN in antigen-induced arthri-
tis. Arthritis Rheum 1998, 41:647–656.
5. Van Meurs JBJ, van Lent PLEM, Holthuysen AEM, Singer II, Bayne EK,
van den Berg WB: Kinetics of aggrecanase and metalloproteinase
induced neoepitopes in various stages of cartilage destruction in
murine arthritis. Arthritis Rheum 1999, 42:1128–1139.
6. Lubberts E, Joosten LAB, van den Bersselaar L, et al: Adenoviral
vector-mediated overexpression of IL-4 in the knee joint of mice
with collagen-induced arthritis prevents cartilage destruction. J
Immunol 1999:in press.
Mast Cells and the Rheumatoid Lesion
David E Woolley and Lynne C Tetlow
University Department of Medicine, Manchester Royal
Infirmary, M13 9WL, UK
The distribution and activation of mast cells (MCs) in the
rheumatoid lesion has been examined by tryptase
immunolocalisation. MCs were observed in all specimens
examined, but their distribution and local concentrations varied,
both within and between specimens. MC activation was
observed at sites of cartilage erosion and was associated with
localised oedema and matrix disruption [1]. Dual immuno-
localisation studies often demonstrated co-distributions of MCs
with the matrix metalloproteinases (MMPs) collagenase 1 and
stromelysin 1, as well as the proinflammatory cytokines TNFa
and IL-1b [2]. Although IL-15 is purported to induce TNFa and
IL-1b expression by cells in vitro [3,4], its production in situ
was not associated with MC activation, as judged by IHC.
The potent mediators of MCs, especially histamine, heparin, and
TNFa, are all likely to modify the phenotype of both synoviocytes
and chondrocytes. The addition of soluble MC products to
synovial fibroblast cultures was shown not only to stimulate MMP
production but also to activate the MMP precursors via
processing by the MC serine proteinases tryptase and chymase
[5]. Experiments using rheumatoid synovial explants and MC
secretagogue, rabbit antibody to human IgE, have shown that
MC activation induced tryptase release, increased PGE2
production, and brought about changes in both MMP [6] and
cytokine production. Subsequent experiments have assessed the
effects of added histamine or heparin on enzymically dissociated
rheumatoid synovial cell cultures with respect to cytokine
production. Collectively, the data demonstrate that MC activation
in the rheumatoid lesion modulates MMP and proinflammatory
cytokine expression by neighbouring cells, thereby suggesting an
important contributory role in mediating matrix degradation and
oedematous changes within microfoci of the rheumatoid lesion.
Work supported by the Arthritis Research Campaign, United
Kingdom.
1. Tetlow LC, Woolley DE: Distribution, activation and
tryptase/chymase phenotype of mast cells in the rheumatoid
lesion. Ann Rheum Dis 1995, 54:549–555.
2. Tetlow LC, Woolley DE: Mast cells, cytokines and metallopro-
teinases at the rheumatoid lesion: dual immunolocalisation
studies. Ann Rheum Dis 1995, 54:896–903.
3. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Interleukin-15
mediates T-cell dependent regulation of tumour necrosis factor-
alpha production in rheumatoid arthritis. Nature Med 1997,
3:189–195.
4. Sebbag M, Parry SL, Brennan FM, Feldmann M: Cytokine stimulation
of T-lymphocytes regulates their capacity to induce monocyte
production of tumour necrosis factor-alpha, but not interleukin-10:
Possible relevance to pathophysiology of rheumatoid arthritis. Eur
J Immunol 1997, 27:624–632.
5. Lees M, Taylor DJ, Woolley DE: Mast cell proteinases activate pre-
cursor forms of collagenase and stromelysin, but not of gelati-
nase A and B. Eur J Biochem 1994, 223:171–177.
6. Tetlow LC, Harper N, Dunningham T, Morris MA, Bertfield H, Woolley
DE: Effects of induced mast cell activation on prostaglandin E and
metalloproteinase production by rheumatoid synovial tissue in
vivo. Ann Rheum Dis 1998, 57:25–32. 9
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Steffen Gay, Thomas Pap, Michael Nawrath,
Juliane K Franz, and Renate E Gay
University Hospital, Zürich, Switzerland
Activation of synovial fibroblasts (SF) by upregulation of proto-
oncogenes is thought to play a major role in rheumatoid joint
destruction. To explore distinct signaling pathways in this activation
we used retroviral gene transfer in the SCID mouse model.
Specifically, we transferred dominant negative (dn) mutants, such
as dn Raf-1 and dn c-myc to inhibit the Ras-Raf-MAPK cascade as
well as the cascade involving myc. FLAG-tagged constructs used
in this study were cloned into the retroviral vector LXSN. The data
show that both Raf- as well as myc-dependent pathways
contribute to the activation of synovial fibroblasts in RA.
Since mutations in PTEN have been described in cancer and
associated with their invasiveness we studied the expression of
this novel tumor-suppressor in RA. Although, no mutations of
PTEN could be detected in RA synovium, only 40% of cultured
RA-SF expressed PTEN, and a down-regulation was observed
at sites of invasion into cartilage. These findings suggest that
endogenous or autocrine down-regulation of this tumor-
suppressor may contribute to the invasive behavior of RA-SF
by maintaining their aggressive phenotype at sites of cartilage
destruction in RA. Most interestingly, the same SF found at
these sites are also the major producers of interleukin-16, a
strong chemoattractant for CD4+ cells.
1. Müller-Ladner U, Gay RE, Gay S: Signalling and effector pathways.
Curr Opin Rheumatol 1999, 11:194–201.
2. Müller-Ladner U, Gay S: The SCID mouse: a novel experimental
model for gene therapy in human rheumatoid arthritis. Drugs of
Today 1999, 35: 379–388.
3. Neidhart M, Wehrli R, Brühlmann P, Michel BA, Gay RE, Gay S: Syn-
ovial fluid CD146 (MUC 18), a marker for synovial membrane angio-
genesis in rheumatoid arthritis. Arthritis Rheum 1999, 42:622–630.
4. Franz J, Kolb SA, Hummel KM, et al: Interleukin-16, produced by syn-
ovial fibroblasts, mediates chemoattractant for CD4+ T lympho-
cytes in rheumatoid arthritis. Eur J Immunol 1998, 28:2661–2671.
5. Jorgensen C, Gay S: Gene therapy in osteoarticular diseases:
where are we? Immunol Today 1998, 19:387–391.
6. Müller-Ladner U, Evans CH, Franklin BN, et al: Gene transfer of
cytokine inhibitors into human synovial fibroblasts in the SCID
Mouse model. Arthritis Rheum 1999, 41:490–497.
Biologic Aspects of Nurse-Like Cells Found in Bone
Marrow and Synovial Tissue of Rheumatoid Arthritis
Patients
Takahiro Ochi
Osaka University Medical School, Osaka, Japan
Using collagen-induced arthritis (CIA) rats, we studied the
origin of synovial stromal cells, which rapidly appeared and
proliferated in joints at the onset of inflammatory polyarthritis,
we partially labelled the bone marrow stromal cells (BMSC)
with fluorescent dye or 3H-Tdr,and analyzed the migration of
labelled BMSC after the immunization with collagen. At the
onset of CIA, BMSC migrated through small canals from the
bone marrow into the affected joint cavities and seemed to
contribute to synovial proliferation in joints [4].
Based on the data above, we were interested in establishing
and characterizing the nurse cell-like stromal cells (NCs) in
bone marrow (RA-BMNC) as well as those in synovial tissue of
rheumatoid arthritis (RA) patients (RA-SNC). RA-BMNC
showed the characteristic cell–cell contact with lymphocytes
(pseudoempeliporesis), resulting in mutual biologic activation,
such as maintaining infiltrating lymphocytes and producing
large amount of cytokines. Those were very similar to the
reactions of RA-SNC reported in our latest paper [2].
Another point of interest was whether NCs could invade the
bone, resulting in erosive changes characteristically observed
in RA patients. Although NCs (both RA-SNC and RA-BMNC)
were shown to produce IL-6, IL-8, and other cytokines, these
were not thought to contribute directly to bone erosion. By co-
culturing NCs with lymphocytes, we found activation in the
production of MMP-1 and MMP-3, and in the expression of
mRNA of both MMP-9 and cathepsin-K. Thus, NCs could be
thought to contribute directly to bone erosion in RA patients.
1. Tomita T, Ochi T, et al: Establishment of nurse-like stromal cells
from bone marrow of patients with rheumatoid arthritis: indication
of characteristic bone marrow microenvironment in patients with
rheumatoid arthritis. Rheumatology 1999.
2. Takeuchi E, Ochi T, et al: Establishment and characterization of
nurse cell-like stromal cell lines from synovial tissues of patients
with rheumatoid arthritis. Arthritis Rheum 1999.
3. Wakisaka S, Ochi T, et al: Possible correction of abnormal rheuma-
toid arthritis synovial cell function by jun D transfection in vivo.
Arthritis Rheum 1998, 41:470–481.
4. Nakagawa S, Ochi T, et al: Bone marrow stromal cells contribute to
synovial cell proliferation in rats with collagen Induced arthritis. J
Rheumatol 1996, 23:2098–2103.
5. Hirohata S, Ochi T, et al: Accelerated generation of CD14+mono-
cyte-lineage cells from the bone marrow of rheumatoid arthritis
patients. Arthritis Rheum 1996, 39:836–843.
6. Tomita T, Ochi T, et al: Phenotypic characteristics of bone marrow
cells in patients with rheumatoid arthritis. J Rheumatol 1994,
21:1608–1614.
Effects of 1a a,25dihydroxyvitamin D3 on matrix
metalloproteinase and prostaglandin E2 production by cells
of the rheumatoid lesion
Lynne C Tetlow and David E Woolley
University Department of Medicine, Manchester Royal
Infirmary, M13 9WL, UK
1a,25dihydroxyvitamin D3 (1a,25D3), the active form of vitamin
D3, through its interaction with intracellular vitamin D receptors
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Synoviocytes, Stromal Cells, and Endothelial Cells in Rheumatoid Arthritis(VDRs), is reported to effect a variety of anabolic and catabolic
events, especially in bone and cartilage tissues [1–3]. VDRs
were demonstrated in most specimens of cartilage–pannus
junction, within synovial pannus tissue, and by chondrocytes
often close to the erosive lesion [4]. In vitro studies have
examined the effects of 1a,25D3 on rheumatoid synovial
explants and monolayer cultures of rheumatoid synovial
fibroblasts (RSFs) and human articular chondrocytes (HACs)
with respect to MMP and prostaglandin E2 (PGE2) production.
Explant cultures exposed to 1a25D3 showed little change in
the production of matrix metalloproteinase (MMP)-1 and MMP-
3, but MMP-9 was markedly suppressed. The expression of
MMP-1, -3, and -9 by RSFs was unaffected by 1a,25D3 alone,
but when stimulated with IL-1b the resultant increase was
signficantly inhibited (~60%) by 1a,25D3. Conversely,
although treatment of HACs with 1a,25D3 alone had little
effect on MMP production, the increase in MMP-1 and -3 seen
with IL-1b stimulation was further enhanced by the
simultaneous addition of 1a,25D3. Such observations
demonstrate that IL-1-activated RSFs and HACs respond
differently to 1a,25D3 exposure, and that the latter has different
effects on the regulatory pathways of specific MMPs. PGE2
production by RSFs stimulated with IL-1b was also significantly
reduced (by up to 70%) following the simultaneous addition of
1a,25D3, a suppression not observed in IL-1b-stimulated HAC
cultures. Moreover, when RSFs were preincubated with
1a,25D3 prior to the addition of IL-1b, subsequent PGE2
production was more markedly suppressed — an observation
suggesting either that 1a,25D3 interferes with the IL-1b
signalling pathway or by its recognised immunosuppressive
functions reported for other cells. Immunohistochemical studies
of the rheumatoid lesion have demonstrated similar
distributions for the expression of VDRs and specific MMPs in
situ — observations that further suggest that 1a,25D3 may be
involved in the modulation of MMP and prostanoid expression
of the rheumatoid lesion.
Work supported by the Arthritis Research Campaign, United
Kingdom.
1. Norman AW, Roth J, Orci L: The vitamin D endocrine system:
steroid metabolism, hormone receptors and biological response
(calcium binding proteins). Endocrine Reviews 1982, 3:331–336.
2. Gerstenfeld LC, Kelly CM, von Deck M, Lian JB: Effect of 1,25dihy-
droxyvitamin D3 on induction of chondrocyte maturation in
culture: extracellular matrix gene expression and morphology.
Endocrinology 1990,  126:1599–1609.
3. Dean DD, Schwartz Z, Schmitz J, et al: Vitamin D regulation of met-
alloproteinase activity in matrix vesicles. Conn Tiss Res 1996,
35:385–390.
4. Tetlow LC, Smith SJ, Mawer EB, Woolley DE: Vitamin D receptors in
the rheumatoid lesion: expression by chondrocytes, macrophages
and synoviocytes. Ann Rheum Dis 1999, 58:118–121.
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Cytokines and Chemokines in Rheumatoid Arthritis
Interleukin-1 Receptor Antagonist Isoforms in Collagen-
Induced Arthritis
Cem Gabay, Richard O Williams*, Debra M Butler*, Brandon
Porter, Marc Feldmann*, and William P Arend
University of Colorado, Denver, Colorado, USA and *Kennedy
Institute of Rheumatology, London, United Kingdom
Interleukin-1 receptor antagonist (IL-1Ra) is a natural IL-1
inhibitor that possesses anti-inflammatory properties in vivo.
IL-1Ra refers to three different proteins, one secreted (sIL-
1Ra) and two intracellular (icIL-1RaI and icIL-1RaII). Levels of
both sIL-1Ra and icIL-1RaI are increased in the rheumatoid
synovium, although icIL-1RaI predominates, particularly in
cultured rheumatoid synovial fibroblasts. Since collagen-
induced arthritis (CIA) reproduces some of the pathologic
characteristics of rheumatoid arthritis, we investigated the
expression of IL-1Ra isoforms in the joints of mice with CIA.
Total RNA and proteins were extracted from whole joints of
immunized mice prior to the development or during the course
of CIA, as well as from synovial tissues obtained from normal
mice, immunized mice before the appearance of arthritis, and
at different time points during the course of CIA (1 to 20
days). The presence of IL-1Ra mRNA and protein isoforms
was examined by RT-PCR, RNase protection assay, and
Western blot analysis. The results showed that sIL-1Ra mRNA
was present at low levels in normal whole joints, as assessed
by RT-PCR, and was further stimulated during arthritis,
whereas icIL-1RaI mRNA was detected only in joints during
CIA. By Western blot analysis, sIL-1Ra protein was detected
in whole joint extracts of immunized mice prior to clinical signs
of CIA, whereas icIL-1RaI was detected only in the joints of
mice with CIA. icIL-1RaII protein followed the production of
sIL-1Ra. icIL-1RaI was the predominant isoform in the isolated
inflamed synovium, with levels increasing during the course of
CIA. In conclusion, sIL-1Ra mRNA was present in low
amounts in normal joints and its levels increased early during
arthritis. In a similar fashion, sIL-1Ra protein was present in the
joints at early stages of CIA. In contrast, icIL-1RaI mRNA and
protein was produced in the joints of mice with CIA in a
delayed manner and was the predominant isoform in the
inflamed synovium.
Chemokines in Rheumatoid Arthritis
Alisa Koch
Northwestern University, Evanston, Illinois, USA
We examined the role of chemokines, which recruit a variety of
cells, including leukocytes and endothelial cells, in rheumatoid
http://arthritis-research.com/supplements/1/S1arthritis (RA). We determined the role of the angiogenic
chemokines IL-8 and epithelial neutrophil activating peptide-78
(ENA-78) in RA using a whole synovial tissue (ST) homogenate
model. RA ST homogenates produced greater levels of these
chemokines than did normal ST homogenates. Angiogenic
chemokines often immunolocalized in proximity to ST blood
vessels. RA ST homogenates contained more angiogenic
activity  in vitro and angiogenic activity in vivo than did normal
ST extracts. Hence, IL-8 and ENA-78 are major contributors to
the RA ST angiogenic activity in vitro and in vivo. To determine
the role of chemokines in the development of arthritis, we
examined inflammation in rats. Anti-ENA-78 diminished
peritoneal neutrophil recruitment in response to rhENA-78 or
lipopolysaccaride. In adjuvant-induced arthritis (AIA), a model
for RA, rats produced serum ENA-78 from day 7 post adjuvant
induction, even prior to the onset of clinical AIA. Joint ENA-78
was elevated in AIA rats from the onset of clinical arthritis.
Prophylactic therapy of rat AIA with anti-ENA-78 prior to
clinical disease onset resulted in a reduction of arthritis and a
decrease in joint IL-1b and tumor necrosis factor (TNF)-a.
These results suggest a role for ENA-78 in the early stages of
AIA development. Efforts aimed at eliminating these angiogenic
chemokines may be of benefit in the therapy of RA.
1. Koch AE, Kunkel SL, Burrows JC et al: The synovial tissue
macrophage as a source of the chemotactic cytokine interleukin-
8. J Immunol 1991, 147:2187–2195.
2. Koch AE, Kunkel SL, Harlow LA et al: Enhanced production of
monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin
Invest 1992, 90:772–779.
3. Koch AE, Polverini PJ, Kunkel SL et al: Interleukin-8 as a
macrophage-derived mediator of angiogenesis. Science 1992,
258:1798–1801.
4. Koch AE, Kunkel SL, Harlow LA, et al: Epithelial neutrophil activat-
ing peptide-78: a novel chemotactic cytokine for neutrophils in
arthritis. J Clin Invest 1994, 94:1012–1018.
5. Koch AE: Angiogenesis: implications for rheumatoid arthritis.
Arthritis Rheum 1998, 41:951–962.
6. Halloran MM, Szekanecz Z, Strieter RM et al: The role of epithelial
neutrophil activating peptide-78 in rat adjuvant-induced arthritis, a
model for human rheumatoid arthritis. J Immunol 1999,
162:7492–7500.
7. Koch AE, Strieter RM: The role of chemokines in disease. Austin: RG
Landes Company (and Chapman and Hall); 1996.
Chemokines and Chemokine Receptors in Lymphocyte
Traffic
Pius Loetscher
Theodor Kocher Institute, University of Bern, Switzerland
Since the discovery of IL-8, about 40 human chemokines and
16 chemokine receptors were characterized. Early on
chemokines were considered as mediators of inflammation, but
with time more and more chemokines were found that function
mainly in the basal traffic of leukocytes, lymphocytes in
particular. Inflammatory chemokines are induced by bacterial
toxins and a number of cytokines, eg IL-1 and TNF, and can be
produced locally in virtually all types of tissues as a
consequence of inflammation or infection. The chemokines
involved in the physiologic traffic of lymphocytes, by contrast,
are produced constitutively in restricted regions. T lymphocytes
express the widest variety of chemokine receptors and the
expression is highly regulated. CXCR3, CCR1, CCR2 and
CCR5, receptors for inflammatory chemokines, are upregulated
by IL-2 in effector/memory T cells and decay rapidly when IL-2
is withdrawn or after stimulation with anti-CD3 and anti-CD28.
Different stimulatory conditions modulate the expression of
other receptors, eg CCR6, CCR7, or CXCR4, which have
homeostatic rather than inflammatory functions. CCR7, for
instance, is present at low levels in resting naive and memory T
cells and is rapidly and transiently upregulated by stimulation
with IL-2 and/or PHA. SLC and ELC, the ligands for CCR7, are
constitutively expressed in secondary lymphoid tissues. The
expression of different receptors on Th1 and Th2 cells provides
a mechanism for their selective recruitment to inflammatory
sites. For instance, the lymphocyte infiltrates in the pannus and
synovial fluid of rheumatoid arthritis joints, which are rich in Th1
cells, are strongly positive for CCR5 and CXCR3.
1. Loetscher P, Moser B, Baggiolini M: Chemokines and their recep-
tors in lymphocyte traffic and HIV infection. Adv Immunol 1999,
55:in press.
2. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998,
392:565–568.
3. Baggiolini M, Dewald B, Moser B: Human chemokines: An update.
Annu Rev Immunol 1997, 15:675–705.
4. Loetscher P, Seitz M, Baggiolini M, Moser B: Interleukin-2 regulates
CC chemokine receptor expression and chemotactic responsive-
ness in T lymphocytes. J Exp Med 1996, 184:569–577.
5. Loetscher P, Uguccioni M, Bordoli L, et al: CCR5 is characteristic of
Th1 lymphocytes. Nature 1998, 391:344–345.
6. Willimann K, Legler DF, Loetscher M, et al: The chemokine SLC is
expressed in T cell areas of lymph nodes and mucosal lymphoid
tissues and attracts activated T cells via CCR7. Eur J Immunol
1998,  28:2025–2034.
7. Loetscher M, Loetscher P, Brass N, Meese E, Moser B: Lymphocyte-
specific chemokine receptor CXCR3: regulation, chemokine
binding and gene localization. Eur J Immunol 1998, 28:3696–3705.
T Cell Maturation in Inflammatory Synovitis
Iain B McInnes
Centre for Rheumatic Diseases, University of Glasgow, United
Kingdom
Functional maturation of T cells towards a Th1 or Th2
phenotype has important implications in the generation and
perpetuation of autoimmune responses. Those factors that
promote and sustain Th1 responses in rheumatoid arthritis
(RA) are unclear. We are currently exploring the functional
effects of the predominantly macrophage-derived cytokines, IL-
12, IL-15 and IL-18, on synovial T cells. We have previously
shown a role for IL-15 in synovial T cell chemokinesis and in
TNFa production through promotion of cytokine-mediated T
cell/macrophage cell contact. We have now extended these
studies to include IL-12 and IL-18. IL-18 mRNA and protein
may be detected by RT-PCR, ELISA, and immunohisto-
chemistry in RA synovial membrane. The absolute levels
present vary considerably between patients. In synergy with IL-
12 and IL-15, IL-18 induces high levels of IFNg, TNFa, and
GM-CSF production. IL-18 mediates effects directly on
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12synovial T cells and macrophages. IL-18 and IL-15 expression
is itself enhanced by IL-1b/TNFa in vitro, suggesting the
existence of feedback loops that provide reciprocal
amplification of Th1 cells and monokine production within the
synovial membrane. These data clearly indicate that synergistic
combinations of T cell activatory cytokines can promote
synovial inflammation. This has important implications for the
choice of therapeutic targets designed to suppress Th1 cell
activity in autoimmune lesions.
1. Wilkinson PC, Liew FY: Chemoattraction of human blood T lym-
phocytes by interleukin-15. J Exp Med 1995, 181:1255–1259.
2. Kotake S, Schumacher HR Jr, Yarboro CH, et al: In vivo gene expres-
sion of type 1 and type 2 cytokines in synovial tissues from
patients in early stages of rheumatoid, reactive, and undifferenti-
ated arthritis. Proc Assoc Am Physicians 1997, 109:286–301.
3. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Interleukin-15
mediates T cell-dependent regulation of tumor necrosis factor-
alpha production in rheumatoid arthritis. Nat Med 1997, 3:
189–195.
4. Thurkow EW, Van der Heijden IM, Breedveld FC, et al: Increased
expression of IL-15 in the synovium of patients with rheumatoid
arthritis compared with patients with Yersinia-induced arthritis
and osteoarthritis. J Pathol 1997, 181:444–450.
5. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R,
Lipsky PE: Interleukin 15 is produced by endothelial cells and
increases the transendothelial migration of T cells in vitro and in
the SCID mouse- human rheumatoid arthritis model in vivo. J Clin
Invest 1998, 101:1261–1272.
6. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY: Soluble IL-15
receptor alpha-chain administration prevents murine collagen-
induced arthritis: a role for IL-15 in development of antigen-
induced immunopathology. J Immunol 1998, 160:5654–5660.
7. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T,
Makino H: Production of interleukin-7 and interleukin-15 by fibrob-
last-like synoviocytes from patients with rheumatoid arthritis.
Arthritis Rheum 1999, 42:1508–1516.
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Autoimmunity in Rheumatoid Arthritis
Citrullinated Peptides as a Substrate for the Detection of
Rheumatoid Arthritis-Specific Autoantibodies
Walther J van Venrooij
University of Nijmegen, The Netherlands
The diagnosis of rheumatoid arthritis (RA) depends primarily on
the clinical manifestation of the disease. The only serologic test
routinely used is the determination of the presence of
rheumatoid factors in the serum. However, these antibodies are
also present in relatively high percentages in other autoimmune
and infectious diseases and in up to 15% of healthy individuals.
Antibodies of a more specific nature were first described by
Nienhuis and Mandema [1], who discovered that RA sera
specifically label the ‘perinuclear factor,’ a component of the
keratohyaline granules in buccal mucosa cells. These
antiperinuclear factor (APF) antibodies are reported to be
present in 49–91% of RA patients, with a specificity of over
70%. Due to technical reasons, the APF test never became
very popular.
We discovered that APF-directed autoantibodies in RA
specifically recognise citrullinated residues in polypeptides [3]
and developed an ELISA procedure using a single cyclic
citrullinated peptide (CCP) as substrate. Our studies showed
that the anti-CCP ELISA assay was positive in about 70% of RA
sera, with a specificity of more than 98% against disease
controls (n>700). Other studies, which will be presented,
corroborate the extreme diagnostic specificity of this auto-
antibody for RA. Therefore, we expect that a serologic test
based on our peptides will be a valuable addition to RA
diagnostics and a help in the decisions to be made concerning
the treatment of early RA patients.
1. Nienhuis RLF and Mandema EA: A new serum factor in patients
with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum
Dis 1964, 23:302–305.
2. Hoet RM, Boerbooms AMTH, Arends M, Ruiter DJ, van Venrooij WJ:
Antiperinuclear factor, a marker autoantibody for rheumatoid
arthritis: colocalisation of the perinuclear factor and profilaggrin.
Ann Rheum Dis 1991, 50:611–618.
3. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte
LBA, van Venrooij WJ: Citrulline is an essential constituent of anti-
genic determinants recognized by rheumatoid arthritis-specific
autoantibodies. J Clin Invest 1998, 101:273–281.
4. Girbal-Neuhauser E et al: The epitopes targeted by the rheumatoid
arthritis-associated autoantibodies are post-translationally gener-
ated on various sites of (pro)filaggrin by deimination of arginine
residues. J Immunol 1999, 162:585–594.
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Mechanism of Arthritis
Collagen Type II-Specific Autoantibodies in Chronic
Inflammatory Joint Diseases
Harald Burkhardt, Christine Unger, Hans-Georg Kraetsch,
Tobias Koller, Joachim R. Kalden, Patrik Wernhof*, and
Rikard Holmdahl*
University of Erlangen-Nuremberg, Erlangen, Germany and
*Lund University, Lund, Sweden
Cartilage components are considered a source of antigens that
could continously fuel tissue-specific immune reactions
directed to the joints. One of the structural components is
collagen type II (CII), the predominant collagen type in
cartilage. Immunization with CII is associated with the
development of an experimental autoimmune arthritis in mice
and rats [1,2]. Collagen-induced arthritis (CIA) is a relevant
experimental model for rheumatoid arthritis (RA) [3]. The
induction of CIA is critically dependent on immunization with
CII in its native conformation, and the onset of arthritis is
preceded by an early rise in IgG autoantibodies (Abs) that are
specific for triple helical structures on CII [4]. The preparation
of a large panel of recombinant chimeric collagen molecules
enabled us to determine precisely the epitopes on CII that are
recognized by monoclonal antibodies established from arthritis
prone DBA/1 mice [5]. The insertion of a series of CII
cassettes into the triple helical recombinant collagen X allowed
the identification of 5 triple helical immunodominant domains of
5–11 amino acid length, to which the majority of the mAbs
bound [5]. In addition, a separate epitope has been identified
that seems to be a major target of the B-cell response in the rat
model of CIA. Interestingly, some of the epitopes that have
been characterized in the rodent arthritis models are also target
structures of the CII-specific IgG response in patients suffering
from severe RA. The results indicate that the arthritogenic B-
cell response is directed to evolutionary conserved CII-
structures.
Supported by a grant from the Deutsche
Forschungsgemeinschaft: SFB 263, project C3 and the
European Commission (Bio4-98-0479).
1. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immuni-
sation against heterologous type II collagen induces arthritis in
mice. Nature 1980, 283:666–668.
2. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II colla-
gen an experimental model of arthritis. J Exp Med 1977, 146:
857–868.
3. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L,
Mo JA: Type II collagen autoimmunity in animals and provocations
leading to arthritis. Immunol Rev 1990, 118:193–232.
4. Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H: Characteri-
zation of the antibody response in mice with type II collagen-
induced arthritis, using monoclonal anti-type II collagen
antibodies. Arthritis Rheum 1986, 29:400–410.
5. Schulte S, Unger C, Mo JA, et al: Arthritis-related B cell epitopes in
collagen II are conformation-dependent and sterically privileged
in accessible sites of cartilage collagen fibrils. J Biol Chem 1998,
273:1551–1561.
Genetic Studies in Experimental Arthritis
Rikard Holmdahl
Lund University, Lund, Sweden
The genetic influence on rheumatoid arthritis (RA) is very
complex with both polygenicity and heterogeneity and most
likely with variable penetrance due to a strong influence by
environmental factors. To make it possible to analyse which
genes are of importance for controlling the disease and to
further understand the basic pathogenesis, we use animal
models in mice and rats. With gene segregation F2
experiments we have identified the major gene regions
controlling the collagen induced arthritis in the mouse and
pristane induced arthritis in the rat. In the rat we have found
that different genes are controlling different phases of the
disease, such as arthritis onset, erosions of the joints and the
chronic development of arthritis. The most important gene
region in both rats and mice is located in the major
histocompatibility complex (MHC). In the mouse we have
proved that the gene in the MHC region, which is responsible
for the effect, is a class II gene called Aq. Interestingly, the
protein encoded by this gene is structurally very similar to the
RA-associated DR4B1*0401/DRA gene product, and mice
expressing the human molecule are susceptible to collagen-
induced arthritis. The function of these molecules is to bind
peptides derived from different infectious agents and then
present them to T lymphocytes. Both Aq and DR4 molecules
bind peptides derived from position 260-273 in type II
collagen. Studies using this structural knowledge show that 1)
T cells recognize predominantly carbohydrate modifications of
the peptide, and 2) the T cells are partially tolerized but can
nevertheless participate in the induction of arthritis. In
conclusion, these studies show that animal models are highly
useful for specific analysis of the pathogenesis of RA by
identifying genes and humanizing mouse strain.
1. Holmdahl R, Andersson EC, Andersen CB, Svejgaard A, Fugger L:
Transgenic mouse models of rheumatoid arthritis. Immunol Rev
1999, 169:161–173.
2. Yang HT, Jirholt J, Svensson L et al: Identification of genes control-
ling collagen-induced arthritis in mice: striking homology with
susceptibility loci previously identified in the rat. J Immunol 1999,
in press:2916–2921.
3. Holmdahl R: Genetics of susceptibility to chronic experimental
encephalomyelitis and arthritis. Curr Opin Immunol 1998, 10:
710–717.
4. Vingsbo-Lundberg C, Nordquist N, Olofsson P et al: Genetic control
of arthritis onset, severity and chronicity in a model for rheuma-
toid arthritis in rats. Nature Genet 1998, 20:401–404.
5. Jirholt J, Cook A, Emahazion T et al: Genetic linkage analysis of col-
lagen-induced arthritis in the mouse. Eur J Immunol 1998, 28:
3321–3328.Role of Cytokines in Cartilage Destruction in Experimental
Arthritis
Wim B van den Berg
University Hospital Nijmegen, The Netherlands
Rheumatoid arthritis (RA) is characterized by major destruction
of the articular cartilage. The mediators TNFa and IL-1
probably play a major role in RA. Following studies in
experimental murine arthritis models, using neutralising
antibodies and scavenging receptors, it became clear that TNF
is a major inflammatory cytokine, whereas IL-1 is the main
destructive cytokine. These observations were recently
confirmed using TNF and IL-1 knock-out mice. Remarkably,
arthritis in TNF-deficient mice was strongly reduced, and yet
ongoing cartilage destruction was still noted. In contrast,
cartilage destruction was minimal in IL-1b knock-out mice.
Apart from inhibition of IL-1, major therapeutic benefit can be
achieved with IL-4 and IL-10 treatment. These cytokines
reduce IL-1 levels and relatively enhance IL-ra. Local gene
transfer with adenoviral IL-4 constructs revealed major
protection against cartilage and bone erosions in experimental
arthritis despite marked inflammation.
Stromelysin seems a pivotal enzyme involved in cartilage
breakdown. It is not an essential MMP in the early proteoglycan
loss, and a major role for aggrecanase seems obvious.
However, stromelysin seems crucial in collagenase activation
and collagen breakdown, and irreversible cartilage erosion is
markedly reduced in arthritis in stromelysin knock-out mice.
Induction of stromelysin-induced neoepitopes and late
destruction can be blocked with IL-1 neutralization.
1. Van den Berg WB: Joint inflammation and cartilage destruction may
occur uncoupled. Springer Semin Immunopathol 1998, 20:149–164.
2. Van Meurs JBJ, van Lent PLEM, Singer II, Bayne EK, van de Loo FAJ,
van den Berg WB: IL-1ra prevents expression of the metallopro-
teinase-generated neoepitope VDIPEN in antigen-induced arthri-
tis. Arthritis Rheum 1998, 41:647–656.
3. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anti-
cytokine treatment of established type II collagen-induced arthri-
tis in DBA/1 mice: a comparative study using anti-TNFa a,
anti-IL-1a a/b b, and IL-1ra. Arthritis Rheum 1996, 39:797–809.
4. Lubberts E, Joosten LAB, van den Bersselaar L, et al: Adenoviral
vector-mediated overexpression of IL-4 in the knee joint of mice
with collagen-induced arthritis prevents cartilage destruction. J
Immunol 1999, 163:4546–4556.
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Synovial Pathophysiology
The Role of COX-2 in Rheumatoid Arthritis Synovial
Tissues
Leslie J Crofford
University of Michigan, Ann Arbor, Michigan, USA
Synovial tissues of patients with rheumatoid arthritis (RA) have
increased expression of COX-2. COX-2 expression in most
tissues is highly regulated with rapid induction in response to
inflammatory stimuli. Anti-inflammatory mediators, particularly
glucocorticoids, inhibit up-regulation of COX-2 expression.
Increased COX-2 expression in synovial tissues is driven by the
pro-inflammatory cytokines IL-1 and TNF-a. These cytokines
stimulate COX-2 transcription by activating transcription factors
including NF-kB and c/EBP. IL-1 also increases mRNA stability.
Modulating influences by other cytokines and growth factors
utilize the STAT family of transcription factors. In addition to
cytokine networks, signalling via cell surface integrins can
increase expression of COX-2. The intracellular pathways
triggered by stimulation of integrins include phosphorylation of
the ERK kinases.
PGE2, the major PG product of COX-2 in synoviocytes, has
been shown to alter matrix metalloproteinase balance and to
increase expression of the angiogenic factor, VEGF. In some
cell types, constitutive over-expression of COX-2 is associated
with phenotypic changes including increased resistance to
apoptosis and production of angiogenic factors. To analyze the
effect of COX-2 on synovial fibroblast-like cells, we have
developed a method for highly efficient constitutive over-
expression of COX-2 using a retroviral vector system. Early-
passage synoviocytes stably transduced to express high levels
of COX-2 can be evaluated for phenotypic changes that
contribute to the pathogenesis of rheumatoid arthritis.
1. Crofford LJ: COX-1 and COX-2 tissue expression: implications and
predictions. J Rheumatol 1997, 24 (suppl 49):15–19.
2. Crofford LJ, Wilder RL, Ristimaki AP, Remmers EF, Epps HR, Hla T:
Cyclooxygenase-1 and -2 expression in rheumatoid synovial
tissues: effects of interleukin-1b b, phorbol ester, and corticos-
teroids. J Clin Invest 1994, 93:1095–1101.
3. Crofford LJ, Tan B, McCarthy CJ, Hla T: NF-k kB is involved in the reg-
ulation of cyclooxygenase-2 expression by interleukin-1b b in
rheumatoid synoviocytes. Arthritis Rheum 1997, 40:226–236.
4. Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular
endothelial growth factor expression in synovial fibroblasts by
prostaglandin E and interleukin-1: a potential mechanism for
inflammatory angiogenesis. FEBS Lett 1995, 372:83–87.
5. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis
in epithelial cells overexpressing prostaglandin endoperoxide
synthase 2. Cell 1995, 83:493–501.
6. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T: Induction of
cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-tran-
scriptional regulation. J Biol Chem 1994, 269:11769–11775.
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Interaction
Jean-Michel Dayer
University Hospital, Geneva, Switzerland
In chronic inflammatory diseases, immunocompetent infiltrating
cells are in the vicinity of or in direct contact with resident cells,
representing the principal pathway for stimulating
proinflammatory and prodestructive cytokines and metallo-
proteinases (MMPs). During the direct contact between
activated T lymphocytes and fibroblasts or mesenchymal-
derived cells, such as synovial cells, membrane-bound TNFa
and IL-1 are the principal cytokines involved in MMP production
by fibroblasts. Therefore, therapies involving Ab to TNFa (ie
soluble receptors or antibodies) and to IL-1 (ie IL-1Ra or soluble
IL-1 receptor type II) are perfectly rational. In the direct contact
between activated TL and monocyte-macrophages (Mf), TL
stimulated by mAb to CD3 favor the production of MMP-1 over
that of TIMP-1, with Th1 cell clones inducing preferentially the
expression of IL-1b and TNFa, and Th2 that of IL-1Ra. The
induction of cytokines and MMPs during TL/Mf contact is
partially inhibited (30–50%) by mAb to CD11 (b>c>a) and
CD69. Contrary to the interaction between TL and fibroblasts,
the blockade of membrane-bound TNFa and IL-1 has no effect
on TL/Mf interaction. The identification of distinct cell-surface
molecules on TL driving either proinflammatory cytokines and
MMP or anti-inflammatory cytokines and TIMP-1 allows the
design of drugs that ensure more precise targeting of
therapeutic intervention. Some of these recent drugs decrease
cell-surface molecules on activated T cells that are involved in
the induction of IL-1b (but not of IL-1Ra) on monocytes.
1. Chizzolini C, Chicheportiche R, Songeon F, Dayer J-M: Human Th1
cells preferentially induce interleukin (IL)-1beta while Th2 cells
induce IL-1 receptor antagonist production upon cell/cell contact
with monocytes. Eur J Immunol 1997, 27:171–177.
2. Coclet-Ninin J, Dayer J-M, Burger D: Interferon-beta not only inhibits
interleukin-1beta and tumor necrosis factor-alpha but stimulates
interleukin-1 receptor antagonist production in human peripheral
blood mononuclear cells. Eur Cytokine Netw 1997, 4:345–349.
3. Loetscher P, Uguccioni M, Bordoli L, et al: CCR5 is characteristic of
Th1 lymphocytes. Nature 1998, 391:344–345.
4. Rezzonico R, Burger D, Dayer J-M: Direct contact between T lym-
phocytes and human dermal fibroblasts or synoviocytes down-
regulates types I and III collagen production via cell-associated
cytokines. J Biol Chem 1998, 273:18720–18728.
5. Burger D, Rezzonico R, Li J-M, et al: Imbalance between interstitial
collagenase (MMP-1) and tissue inhibitor of metalloproteinase-1
(TIMP-1) in synoviocytes and fibtroblasts upon direct contact with
stimulated T lymphocytes : involvement of membrane-associated
cytokines. Arthritis Rheum 1998, 41:1748–1759.
6. Déage V, Burger D, Dayer J-M: Exposure of T lymphocytes to
leflunomide but not to dexamethasone favors the production by
monocytic cells of interleukin-1 receptor antagonist and the tissue
inhibitor of metalloproteinases-1 over that of interleukin-1beta and
metalloproteinases. Eur Cytokine Netw 1998, 9:663–668.
7. Burger D, Dayer J-M: Interactions between T cell plasma mem-
branes and monocytes. In T Cells in Arthritis. Edited by Miossec P,
van den Berg WB, Firestein GS. Basel: Birkhäuser, 1998:111–128.
Life and Death in the Synovium
Gary S Firestein
University of California at San Diego School of Medicine, San
Diego, California, USA
Studies of the p53 tumor suppressor gene in rheumatoid
arthritis (RA) have demonstrated somatic mutations in
rheumatoid synovium and synoviocytes but not in RA skin or OA
synovium [1]. Most of the mutations identified in RA samples are
also present in various neoplastic diseases, suggesting that they
are dominant negative. To determine if RA mutations are
dominant negative, site directed mutagenesis was used to
produced two RA mutants: Asparagine>Serine at codon 239
(N239S) and Arginine>Stop at codon 213 (R213*) [2]. Co-
transfection experiments were performed using a construct
containing the p53-responsive bax promoter construct with a
luciferase reporter gene (bax-luc). Low levels of bax promoter
activity were detected in HS68 cells co-transfected with bax-luc
and empty vector, N239S, or R213*, indicating that the RA
mutant lacked transcriptional activity. Transfection with wt and
bax-luc led to a 10-fold increase in luciferase expression. When
the wt gene was co-transfected with either of the mutants, there
was a dose dependent inhibition of bax promoter activity. These
data indicate that at least 2 of the p53 mutants identified in RA
joint samples are dominant negative and suppress endogenous
wild type p53 function.
Greater than 80% of the p53 mutations identified in synovium
and cultured synoviocytes were G/A and T/C transitions. Such
mutations are characteristic of oxidative deamination by nitric
oxide and suggest that the mutagenic environment in
chronically inflamed synovium contributes to alterations in the
p53 gene. Mutations accumulate over time and specific
alterations in the p53 gene, ultimately contributing to
synoviocytes autonomy and perpetuation of disease. Other
genes might also be altered in arthritis, and mutations in the H-
ras gene were also recently reported in RA and OA synovium.
The occurrence of somatic mutations secondary to
inflammation indicates that a window of opportunity exists in
RA after the initiation of disease, but before establishment of
aggressive pannus.
1. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR: Somatic
mutations in the p53 tumor suppressor gene in rheumatoid arthri-
tis synovium. Proc Natl Acad Sci USA 1997, 94:10895–10900.
2. Han Z, Boyle DL, Shi Y, Green DR, Firestein GS: Dominant negative
p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999,
42:1088–1092.
Apoptosis in Rheumatoid Synoviocytes
Kusuki Nishioka
Institute of Medical Science, St. Marianna University School
of Medicine, Kawasaki, Japan
Rheumatoid arthritis (RA) is systemic autoimmune disease
characterized by synovial proliferation and infiltration of various
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Synovial Tissue
Ulf Andersson
Karolinska Hospital, Stockholm, Sweden
Computer-based assessment of images acquired in a
microscope requires an attached video camera transferring the
images to a computer and a screen. The analytical decisions
made by the computer equipped with a special software
program will be displayed on the screen in discriminating
pseudocolors, enabling the operator to monitor and accept or
discard the results of a given field. Quantification of cells
expressing cell surface antigens or intracellular antigens can be
readily done in immunohistochemically stained tissue sections
from synovial tissue. Conventional microscopy is a good tool
for counting but poor at measuring areas, staining intensity, or
distances, which can be handled in a superior way by
computer-assisted analysis. We have successfully applied this
technology to quantify the incidence of various cell types,
intimal layer thickness, and cytokine-producing cells in
rheumatoid synovial tissue specimens. Computerized image
analysis offers a major advantage in sequential studies to
evaluate changes in response to therapy.
1. Bjork L, Fehniger TE, Andersson J, Andersson U: Computerized
assessment of multiple human cytokines at the single cell level
using image analysis. J Leukocyte Biol 1996, 59:287–295.
2. Litton M, Dohlsten M, Hansson J, et al: Tumor therapy with an anti-
body-targeted superantigen generates a dichotomy between local
and systemic immune responses. Am J Pathol 1997, 150:
1607–1618.
3. Andersson J, Fehniger TE, Patterson BK, et al: Early reduction of
immune activation in lymphoid tissue following highly active HIV
therapy. AIDS 1998, 12:123–129.
4. Cunnane G, Bjork L, Ulfgren A-K, FitzGerald O, Bresnihan B, Anders-
son U: Quantitative analysis of synovial membrane inflammation:
a comparison between automated and conventional microscopic
measurements. Ann Rheum Dis 1999, 58:493–499.
5. Litton M, Dohlsten M, Rosendahl A, et al: The distinct role of CD4+
and CD8+ T cells during the anti-tumor effects of targeted super-
antigens. Br J Cancer 1999, in press.
6. Andersson U, Litton M, Fehniger TE, Ulfgren AK, Andersson J: Detec-
tion and quantification of cytokine-producing cells by immunos-
taining. In: Detection and quantification of gene expression. Edited by
Patterson BK. New York: Springer–Verlag; 1999, in press.
Synovial Tissue Analysis in Clinical Studies
Barry Bresnihan
St. Vincent’s Hospital, Dublin, Ireland
Synovial tissue analysis may provide new insights in studies of
the clinical course and outcome, response to treatment and
disease mechanisms [1]. In a prospective clinical study of
acute phase serum amyloid A (A-SAA) (the principle
component of amyloid deposition) in early rheumatoid arthritis
(RA), strong correlations with disease activity and response to
therapy were observed [2]. A-SAA production by the liver is
regulated by the pro-inflammatory cytokines IL-1, TNF-a and IL-
6 [3]. Little is known about A-SAA production at peripheral
sites of inflammation. This study was undertaken to investigate
if A-SAA is produced by inflamed synovium in RA and other
arthropathies.
Synoyiocytes were cultured following arthroscopic biopsy from
patients with early arthritis. Total RNA was analysed for A-SAA
mRNA using Northern blot analysis and RT-PCR.
Immunohistochemistry was performed on frozen tissue
sections using a polyclonal rabbit anti-human antibody. Using
immunohistochemistry, A-SAA protein was demonstrated in the
superficial layer of the synovial intima and in vascular
endothelial cells. A-SAA mRNA was not detectable by
Northern blot analysis in cultured synoviocytes. The RT-PCR
technique, which is 100–1000 times more sensitive, resulted
in the detection of constitutive expression of A-SAA. A
fragment of 335 bp nucleotides was identified by RT-PCR and
was verified by Southern blot analysis. A-SAA mRNA
expression was investigated in cultured synoviocytes in
response to inflammatory cytokines. Initial data indicates that
IL-1, TNF-a and IL-6 are important regulators of A-SAA
expression in these cells.
This is the first study to demonstrate A-SAA gene expression in
human synovium. Local production of A-SAA, demonstrated by
both RT-PCR and immunohistochemistry, suggests a
physiological role for A-SAA at sites of inflammation. 17
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inflammatory cells. The process of disease progression,
characterized by hyperplasia of synoviocytes, mainly of synovial
fibroblasts, results in cartilage and bone destruction.
Proliferation of synoviocytes is, however, not limitless, and
spontaneous arrest and remission of synovial proliferation are
occasionally observed. Previous studies from our laboratories
as well as by other investigators have demonstrated that RA
synoviocytes express functional Fas antigen (CD95/APO-1)
and that these cells undergo Fas-mediated apoptosis both in
vivo and in vitro. These findings suggest that Fas-mediated
apoptosis may play a critical role in the regression of synovial
hyperplasia in RA. Identification of regulatory mechanisms in
RA synoviocytes may provide important insights and may lead
us to establish novel strategies for RA therapy. We describe a
current study by our laboratory on the regulatory mechanisms
of apoptosis in RA, especially FasL and FADD gene transfer
into inflamed synovium to induce remission stage and propose
a novel strategy termed ‘apomodulation’ in the treatment of RA.
http://arthritis-research.com/supplements/1/S11. Bresnihan B, Tak PP: Synovial tissue analysis in rheumatoid arthri-
tis. Balliere’s Clini Rheumatol 1999, 13:85–99.
2. Cunnane G, Grehan S, Geoghegan S, et al: Serum amyloid A in the
assessment of early inflammatory arthritis. J Rheumatol 1999, in
press.
3. Steel DM, Whitehead AS: The major acute phase reactants: C-
reactive protein, serum amyloid P component and serum amyloid
A protein. Immunology Today 1994, 15:81–88.
Predictors of Early Bone Erosion in Patients With Synovitis
of Recent Onset
J Lee, R Goldbach-Mansky, C Hitchon, C Danning, M
Aringer, J Hoxworth, J Smolen, T Palusuo, R Schumacher, D
Smith, R Wilder, and Hani El-Gabalawy
National Institute of Arthritis and Musculoskeletal and Skins
Diseases, Bethesda, Maryland, USA
To identify risk factors for the development of radiographic
erosions early in the course of inflammatory arthropathies, an
inception cohort of 238 patients with peripheral joint synovitis
of less than one year duration was evaluated. Of these patients,
70 (28%) had early RF+RA, 36 (15%) had RF-RA, 43 (18%)
had spondylarthropathy, and 89 (37%) had undifferentiated
arthritis. Patients underwent clinical, serological and
radiographic evaluation, HLA typing, and closed synovial
biopsy of an affected joint. A total of 23% of patients had
multiple radiographic erosions, with RA patients having the
highest frequency (37%). The presence of multiple erosions
was associated with the presence of the shared epitope only in
the RF-RA patients (OR 9.9, P<0.01). Anti-Sa antibodies were
associated with the presence of multiple erosions in both RF+
and RF– patients (odds ratios 2.0 and 6.3 respectively), but
numbers were too small to reach statistical significance. The
presence of either SE or anti-Sa was highly associated with
erosions in the RF-RA patients (odds ratio of 25.7, P<0.05).
As elevated tissue and serum levels of the gelatinases (MMP-2
and MMP-9) have been associated with enhanced
invasiveness in cancer, we tested the hypothesis that elevated
levels and activity of the gelatinases were associated with the
presence erosions. Serum levels of active MMP-2 and -9 were
measured in a subset of 45 RA, 21 non-RA patients, and 4
normal volunteers. Tissue expression of MMP-2,-9,-14 and
TIMP-1, 2 were assessed using immunohistology and synovial
activity of MMP-2 and -9 were measured using gel zymography.
Serum levels of total and active MMP-2 and -9 did not predict
erosions. Patients with erosions had higher synovial tissue
levels of active MMP-2 than patients with no erosions
(3.5±2.1ng/mg vs 1.9±2.5ng/mg, P=0.04). MMP-9 levels
tended to be higher in the patients with erosive disease,
although the range of expression was very wide. No other
immunohistologic parameter correlated with the presence of
early erosions.
In this cohort of patients with early synovitis, the presence of
either shared epitope or anti-Sa antibodies was associated
with early erosion formation, particularly in patients with RF-RA.
In the synovial tissues of these patients, high levels of MMP-2
activity are the most closely associated with erosive disease.
Histopathology of Bone Erosions in Rheumatoid Arthritis
Ellen Gravallese, Cathy Manning, Alfie Tsay, Akifumi Naito,
and Steven Goldring
New England Baptist Bone and Joint Institute, Harvard
Institutes of Medicine, Boston, Massachusetts, USA
Focal bone erosions in areas of pannus invasion are a hallmark
of established rheumatoid arthritis (RA). We have utilized
histochemical techniques and in situ hybridization to
demonstrate that the cells responsible for these bone erosions
express an osteoclast phenotype. Our results indicate that the
multinucleated cells in resorption lacunae in continuity with
pannus express abundant tartrate resistant acid phosphatase
(TRAP), cathepsin K and calcitonin receptor (CTR) mRNA.
Although CTR expression is restricted to multinucleated and
mononuclear cells on the mineralized tissue surfaces,
numerous TRAP positive mono- and multinucleated cells are
present within the pannus remote from bone surfaces. We
speculate that these TRAP positive cells represent osteoclast
precursors that are recruited to the pannus tissue. Interaction
of these cells with bone and calcified cartilage provides the
additional signals that induce these cells to differentiate into
resorbing cells with a definitive osteoclast phenotype. To
further investigate the specific factors involved in the
differentiation of osteoclasts in RA we have initiated studies to
examine the expression of a recently described regulator of
osteoclastogenesis, osteoclast differentiation factor (ODF), a
member of the membrane associated TNF-ligand family, and its
putative receptor on osteoclast precursors, the receptor
activator of NF-kB (RANK). Analysis of synovial tissues by RT-
PCR from eight patients with RA, five with juvenile arthritis and
three with normal synovium reveals the expression of mRNA for
ODF in 7/8 RA, 5/5 juvenile arthritis, and 0/3 normal cases.
These data provide preliminary evidence that ODF may be an
important factor in the pathogenesis of osteoclast-mediated
bone resorption in RA.
1. Gravallese EM, Harada Y, Wang JT, Thornhill TS, Juppner H, Goldring
SR: Identification of cell types responsible for bone resorption in
rheumatoid arthritis and juvenile rheumatoid arhtritis. Am J Path
1998, 152:943–951.
2. Darling JM, Goldring SR, Harada Y, Handel ML, Glowacki J,
Gravallese EM: Multinucleated cells in pigmented villonodular syn-
ovitis and giant cell tumor of tendon sheath express features of
osteoclasts. Am J Path 1997, 150:1383–1394.
3. Gravallese EM, Handel ML: Synovial tissue analysis in rheumatoid
arthritis. In UpToDate. Edited by Rose BD. Wellesley MA: UpToDate,
1998.
4. Suda T, Nakamura I, Jimi E, Takahashi N: Regulation of osteoclast
function. J Bone Miner Res 1997, 12:869–879.
5. Goldring SR, Polisson RP: Bone disease in rheumatological disor-
ders. In Metabolic Bone Disease, Second Edition. Edited by Avioli L
and Krane SM. San Diego: Academic Press, 1998:621–635.
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Shunsei Hirohata and Jo Sakakibara
Tokyo University School of Medicine, Tokyo, Japan
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by a progressive destruction of joints. Previous
studies identified capillary damage, edema, vascular
congestion, and cellular infiltrates as earlier pathological
changes in the rheumatoid synovium of disease of less than 6
weeks duration. However, it is possible that even 6 weeks is
too late to identify some important early changes, since recent
studies have suggested that the debut of RA already
represents a chronic phase of the disease. In this report, we
show the histological features of the synovium in early RA.
Synovial tissues were obtained by arthroscopic synovectomy
from three patients who had had episodes of monoarthritis for
one or two years prior to the development of typical RA,
satisfying the American Rheumatism Association 1987 criteria.
As controls, four patients with osteoarthritis in the knee joints
and, two patients with systemic lupus erythematosus and
aseptic necrosis of the knee joints were additionally studied.
The common histologic findings of the synovium of the early RA
patients on the light microscopy revealed very mild proliferation
of lining cells with capillary congestion and mild mononuclear
cell infiltration. However, similar changes were also detected in
the control patients. Of note, a proportion of the biopsied
synovium showed only angioneogenesis without either lining
cell proliferation or mononuclear cell infiltration, which was not
detected in the control patients. The results thus suggest that
angioneogenesis may precede any other features, such as
lining cell proliferation and cellular infiltration in early RA.
Moreover, it is most likely that angioneogenesis might be the
feature that is most proximal to the etiology in early RA.
1. Schumacher HR Jr, Bautista BB, Krauser RE, Mathur AK, Gall EP:
Histological appearance of the synovium in early rheumatoid
arthritis.  Semin Arthritis Rheum 1994, 23 (suppl 2):3–10.
2. Kraan MC, Versendaal H, Jonker M et al: Asymptomatic synovitis
precedes clinically manifest arthritis. Arthritis Rheum 1998,
41:1481–1488.
3. Hirohata S, Sakakibara J: Angioneogenesis as a possible elusive
triggering factor in rheumatoid arthritis. Lancet 1999, 353:1331.
4. Takahashi T, Kalka C, Masuda H et al: Ischemia- and cytokine-
induced mobilization of bone marrow-derived endothelial progen-
itor cells for neovascularization. Nat Med 1999, 5:434–438.
5. Peacock DJ, Banquerigo ML, Brahn E: Angiogenesis inhibition sup-
presses collagen arthritis. J Exp Med 1992, 175:1135–1138.
Synovial Tissue Response to Treatment: The Effects of
IFN-b b Treatment in Rheumatoid Arthritis Patients
Paul P Tak
Division of Clinical Immunology and Rheumatology, Academic
Medical Center, Amsterdam, The Netherlands
Analysis of serial synovial biopsy specimens may provide useful
surrogate end points for clinical studies. This approach could
lead to a rapid screening method requiring relatively low
numbers of patients for predicting the effects of novel anti-
rheumatic drugs [1]. Before the therapeutic effects on synovial
tissue (ST) could be properly analyzed, studies were
conducted to establish the methods for synovial biopsy [2],
microscopic examination [3], the relationship between the
immunohistologic characteristics and disease activity [4], and
the features of serial biopsies after placebo treatment [5].
This approach was used to evaluate the effects of IFN-b therapy
on ST from RA patients [6]. Eleven patients were treated for 12
weeks with purified natural fibroblast IFN-b (Frone®, Ares-
Serono) s.c. 3 times weekly with the following dosages: 6
million units (MIU) (n=4), 12 MIU (n=3), and 18 MIU (n=4).
Synovial biopsy specimens were obtained by needle
arthroscopy at 3 time points: directly before and at 1 month and
3 months after initiation of treatment. Immunohistologic analysis
was performed to detect CD3, CD38, CD68, CD55, TNF-a, IL-
1b, IL-6, MMP-1, and TIMP-1. A significant reduction in the
mean immunohistologic scores for CD3+ T cells, CD38+
plasma cells, and expression of IL-1b, IL-6, MMP-1, and TIMP-1
was observed in ST after treatment. The scores for CD68+
macrophages and TNF-a expression also tended to decrease,
but these differences did not reach statistical significance. The
inhibitory effects of IFN-b on MMP-1 production by fibroblast-
like synoviocytes were confirmed by in vitro studies.
The significant changes in synovial tissue after IFN-b treatment
support the view that IFN-b therapy has immunomodulating
effects on rheumatoid synovium and might help to diminish
both joint inflammation and destruction.
1. Tak PP, Breedveld FC: Analysis of serial biopsies as a screening
method for predicting the effects of therapeutic interventions. J
Clin Rheumatol 1997, 3:186–187.
2. Youssef PP, Kraan M, Breedveld F, et al: Quantitative microscopic
analysis of inflammation in rheumatoid arthritis synovial membrane
samples selected at arthroscopy compared with samples obtained
blindly by needle biopsy. Arthritis Rheum 1998, 41:663–669.
3. Kraan MC, Haringman JJ, Ahern, MJ, Breedveld FC, Smith MD, Tak
PP: Digital image analysis for the quantification of the cell infil-
trate in synovial tissue. Rheumatology (In press)
4. Tak PP, Smeets TJM, Daha MR, et al: Analysis of the synovial cellu-
lar infiltrate in early rheumatoid synovial tissue in relation to local
disease activity. Arthritis Rheum 1997, 40:217–225.
5. Smeets TJM, Kraan MC, Versendaal H, Breedveld FC, Tak PP: Analysis
of serial biopsies in rheumatoid arthritis patients: description of a
control group without clinical improvement after treatment with
recombinant human interleukin-10 or placebo. J Rheumatol (In press).
6. Smeets TJM, Dayer JM, Kraan MC, et al: The effects of interferon-b b
treatment on synovial inflammation and metalloproteinase produc-
tion in patients with rheumatoid arthritis. Arthritis Rheum (In press).
Fibroblastoid Synoviocytes: Their Intrinsic and Disease-
Modified Phenotype as Revealed by a Differential
Subtraction Library Approach
Robert Winchester
Columbia University, New York, New York, USA
Through their unique and increasingly defined pattern of gene
expression, the fibroblastoid intimal synoviocytes appear to be 19
http://arthritis-research.com/supplements/1/S1differentiated to perform a series of functions critical to the
biologic function of the normal joint, including responsibility for
its developmental patterning and the maintenance of its
structural integrity. This phenotype also appears to confer the
potential for fostering the development and synovial localization
of the autoimmune response underlying rheumatoid arthritis,
and to participate in joint destruction. The use of synoviocyte
lines cultured from either rheumatoid arthritis or osteoarthritis
synovia has facilitated progress in the process of gene
discovery, although it remains to be determined the extent to
which the distinctive phenotype of cells from rheumatoid
arthritis reflects persistent modulation by exposure to the
inflammatory microenvironment and the extent to which lines
from osteoarthritis synovia include large proportions of more
conventional fibroblasts from deeper layers of the joint rather
than intimal synoviocytes. The possible explanations of the
distinctive phenotype include: being intrinsic to the
fibroblastoid intimal synoviocyte lineage, persistent modulation
by inflammation, or that the over expression phenotype reflects
a genetically determined increased expression due to a disease
predisposing regulatory polymorphism. Other genes that are
identified as equivalently expressed in both lines cultured from
either rheumatoid arthritis or osteoarthritis synovia are likely to
be related to the more general role of members of the
fibroblastoid lineage, or at least those developing in the
synovial milieu.
The profile of genes being identified by us and in other
laboratories are relevant to novel functions exhibited by this
lineage in the normal joint. Fibroblastoid intimal synoviocytes
differ from other fibroblastoid lineage cells in that the structure
of the intimal lining involves both homotypic cell–cell
interactions and heterotypic interactions with monocytes.
Genes encoding receptors selectively expressed in
synoviocytes are being identified that appear to be involved in
these interactions as well as mediating cell–connective tissue
matrix interactions. Additional genes are being recognized that
appear responsible for the localization and guidance clues that
result in the entrance and differentiation of monocytes in the
intima, including certain chemokines such as SDF-1. An
exaggeration of this mechanism is likely relevant to
nonantigen-specific entry of lymphocytes and monocytes into
the joint in inflammation. Genes implicated in the patterning of
the central nervous system are expressed constitutively at high
levels in synoviocytes, perhaps reflecting a role in the
development of the joint architecture. A last group of genes is
thought to be induced by cellular activation pathways and their
expression could relate to the modulation of the synoviocyte by
inflammation.
The Effects of ‘Pulse’ Corticosteroids on Mediators of
Inflammation and Joint Damage in the Rheumatoid
Synovium
Peter Youssef
University of New South Wales, Sydney, Australia
We have demonstrated that the dramatic reduction in clinical
inflammation in rheumatoid arthritis (RA) joints caused by high-
dose ‘pulse’ methylprednisolone (MP) is associated with a
rapid reduction in neutrophil ingress. MP also causes a
reduction in L-selectin and b2 integrin expression in synovial
fluid neutrophils. To determine the mechanisms of these
effects, arthroscopic synovial biopsies were taken before and
24 hours after MP and at disease relapse, and the expression
of various cytokines and cell adhesion molecules were
determined using standard immunohistochemical techniques. It
was observed that MP caused a marked reduction in TNFa, IL-
8, E-selectin, and ICAM-1 expression in the synovial membrane
with 24 hours, thereby reducing the chemotactic gradient for
neutrophils as well as neutrophil activation and adhesion in the
synovial membrane. Disease relapse was associated with re-
expression of these molecules. There was no effect on IL-1b,
IL-1Ra, P-selectin, or PECAM expression.
Although no effect on macrohage infiltration was observed,
there was a reduction in the expression of MCP-1 and MIP-1a
expression in the synovial membrane within 24 hours of MP.
The effects of glucocorticoids on joint damage remain
controversial. We have observed that MP significantly reduces
MMP-1 and TIMP-1 expression but not MMP-3 expression in
the rheumatoid synovium.
The role of the S100 proteins in RA remains unclear. We have
observed that the expression of S100A8 and -A9 (MRP8 and
-14) is increased by MP. The significance of these findings has
yet to be determined.
1. Youssef PP, Haynes DR, Triantafillou S, et al: Effects of pulse
methylprednisolone on proinflammatory mediators in peripheral
blood, synovial fluid and the synovial membrane in rheumatoid
arthritis. Arthritis Rheum 1997, 40:1400–1408.
2. Youssef PP, Triantafillou S, Parker A, et al: Effects of pulse methyl-
prednisolone on cell adhesion molecules in the synovial mem-
brane in rheumatoid arthritis: reduced E-selectin and ICAM-1
expression. Arthritis Rheum 1996, 39:1970–1979.
3. Youssef PP, Cormack J, Evill C, et al: Neutrophil trafficking into
inflamed joints in rheumatoid arthritis and the effect of methyl-
prednisolone. Arthritis Rheum 1996, 39:216–225.
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Paul Emery
University of Leeds, United Kingdom
A better understanding of the pathogenesis of rheumatoid
arthritis (RA) has led to a number of new therapeutic
possibilities. The clinical introduction of such novel
pharmaceutical molecules is usually delayed because of
difficulty in assessing their in vivo potential. Furthermore there
is considerable wastage in early development as phase I and II
studies do not formally assess true disease modification,
concentrating instead on symptomatic efficacy and toxicity. The
availability of targeted therapies, such as blockade of TNF,
highlight the inadequacy of such an approach.
The rapid advances in imaging techniques have revolutionised
the possibilities for drug development. The modalities include
small needle arthroscopy with synovial biopsy, dynamic
enhanced high-field magnetic resonance imaging (MRI), fan-
beam dual energy X-ray absorptionometry (DXA) and high
resolution ultrasound (HRUS). Instead of large numbers of
patients being studied using insensitive end points, proof of
concept/mode of action studies undertake intensive
investigation of highly selected patients, using predetermined
end points usually involving the primary target organ.
Multidimentional imaging studies have been undertaken to
directly examine novel therapies, which include intra-articular
anti-CD4, combination monoclonal antibodies, stem-cell
transplantation, and comparisons of novel pharmaceutical
agents, eg, the direct effect of corticosteroids on the synovium.
These studies, which are scored in a blinded fashion, have
shown significant changes in small numbers of patients.
Depending on the type of disease, the imaging can focus on
either the synovium (knee) or the synovial/bone interface (hand).
The value of individual techniques will be discussed and a
developmental plan for therapies in arthritic disease proposed.
1. Veale DJ, Reece RJ, Parsons W, et al: Intra-articular primatised anti-
CD4: efficacy in resistant rheumatoid knees. A study of combined
arthroscopy, magnetic resonance imaging, and histology. Ann
Rheum Dis 1999, 58:342–349.
2. IA Corticosteroids prevent progression of erosions in MTX treated
early RA-An MRI/HRUS study. Arthritis Rheum 1998, 41(suppl):
S238.
Lessons Learned From Gene Therapy Approaches
Chris H Evans
University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania, USA
Our ability to transfer genes to the synovial lining of joints allows
the roles of various gene products in synovitis to be studied in
novel ways. One strategy uses adenoviral vectors to transfer
genes of interest to the synovial lining of normal and inflamed
rabbits’ knee joints. Rabbits are used because their knee joints
are sufficiently large for reproducible intra-articular injection and
lavage. Moreover, it is possible to study the responses of
articular cartilage to disturbances occurring in the synovium.
These studies need to be carefully performed as the adenoviral
vector itself has inflammatory properties. Nevertheless, it is
possible to gain important new information in this way.
When introduced into naive joints, vectors carrying IL-1b
provoke a dramatic synovitis and pannus, which severely erode
the adjacent cartilage. They also trigger systemic disturbances,
including fever and weight loss. Oddly, the introduction of
similar vectors carrying TNF produces only mild inflammatory
and chondrodestructive changes. The TGF-b gene, in contrast,
generates a massive fibrosis. The IGF-I and BMP-2 genes, on
the other hand, produce few synovial changes and modestly
elevate the synthesis of proteoglycans by cartilage.
When introduced into joints with antigen-induced arthritis,
adenoviral vectors carrying genes encoding bivalent IL-1sR type
I protect the articular cartilage and reduce the influx of
leukocytes into the joint space. They do not, however, reduce
synovitis or swelling. Similar vectors carrying bivalent TNFsR
type I have no effect on cartilage and are only very weakly anti-
inflammatory. Co-introduction of both vectors is strongly anti-
inflammatory and chondroprotective. In animals with bivalent
disease, there is also amelioration of disease in the contralateral
knee joint that was not injected with the therapeutic genes. An
even stronger effect on synovitis and associated joint
pathologies was obtained with the viral IL-10 gene, which also
produced a marked contralateral response. This effect has been
reproduced in collagen-induced arthritis in mice.
New Vectors and New Targets for Gene Therapy in
Rheumatoid Arthritis
C Jorgensen, F Apparailly, and J Sany
University Hospital Lapeyronie, Montpellier, France
The immunopathology of rheumatoid arthritis (RA) is associated
with the production of inflammatory cytokines (IL-1, TNF-a, IL-6),
synovial proliferation, and cartilage invasion. A sustained 21
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http://arthritis-research.com/supplements/1/S1increase in the amounts of cytokine antagonists obtained
through gene therapy should inhibit the process. Targeting of a
single molecule, however, is unlikely to be sufficient for the
reversal of the complex molecular and cellular events that lead
to the progressive destruction of cartilage and bone in RA.
Several groups have developed efficient gene transfer of
therapeutic molecules in experimental arthritis (IRAP, TNF-R, IL-
10, TGF-b) through retrovirus (ex vivo procedure) or intra
articular (i.a) or systemic adenoviral delivery (in vivo procedure).
To increase the efficiency of gene transfer, new targets have
been identified. They include transduction signal inhibitors
(super repressor IkBa), synovial-cell activation cascade (c-Jun,
Ras antagonist), and synovial apoptosis (fas ligand, p53 or Rb
gene transfer). Suicide gene (HSV tk) may also be
administered i.a. and induces a ‘genetic synovectomy’ after IV
gancyclovir treatment. Angiogenesis may also be inhibited after
gene transfer (antagonist of aVb3 or plasminogen activator
[PA], PF4, angiostatin). We will present new data showing a
decrease in arthritic severity after adenoviral transfer of PA
antagonist. All of these targets may be combined with the
cytokine approach.
Progress in the development of safe nonviral gene delivery has
been made in recent years. Liposome HVJ is efficient to deliver
DNA in chondrocytes and synoviocytes without systemic
diffusion. Efficient HSV tk gene transfer has been achieved in
the synovium by local injection of naked DNA plasmids.
Plasmid injection in the muscle combined with electroporation
increases by 1000 the serum concentration of cytokine.
AAV vectors are parvoviruses designed to be gutless and
efficient for direct gene transfer in vivo. Interestingly, only a
weak immune response against the transgene product is
detected in animals following AAV-mediated gene transfer,
allowing long-term expression (>18 months). These vectors are
suitable to transfer genes in the synovial tissue. Using the
SCID mouse model, we showed the feasibility of gene transfer
in human tissue with AAV recombinant vectors.
For gene therapy to be an effective and safe approach for the
clinical management of disease, gene expression must be
highly regulated. The design of safe vectors to enhance the
duration of transgene expression and to co-transfer regulatory
genes is an active area of research.
Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis
Joachim R Kalden, Harald Burkhardt,
and Hendrik Schulze-Koops
University of Erlangen-Nuremberg, Erlangen, Germany
Monoclonal antibodies (mAbs) to CD4 have been employed in a
variety of studies to patients with active rheumatoid arthritis (RA) in
an attempt to control disease progression not only by preventing T
cell activation but also by inducing tolerance to the putative
autoantigen(s) [1,2,5]. Initial open labeled clinical trials have
provided encouraging clinical results [1,2,4]. However, randomized
controlled studies with chimeric immunoglobulins have largely
failed to demonstrate a significant benefit of anti-CD4 mAbs over
placebo [1,2,5]. Following those disappointing trials, favorable
results of several dose-finding studies with high dosages of
nondepleting CD4 mAbs were recently presented [1,2,6].
Whereas the mechanisms underlying the clinical benefit remain to
be elucidated, it appears to be clear that depletion of CD4 T cells
cannot explain clinical efficacy. Moreover, the data are consistent
with the hypothesis that long lasting successful treatment of RA
with mAb to CD4 might require long-term inhibition of peripheral T
cell functions by non-depleting mAbs to CD4. Future studies are
necessary to delineate precisely the dosing requirements for
clinical benefit and to elucidate the mode of actions of anti-CD4
mAbs. Exciting new data that are indicative of a modulation of the
detrimental Th1-dominated immune response in RA by anti-CD4
mAbs [6] warrant further investigation. Finally, data from animal
studies suggest that new promising therapeutic perspectives in
man might result from combining anti-CD4 mAbs with other
biologic therapeutics [1,7,8].
1. Kalden JR, Breedveld FC, Burkhardt H, and Burmester GR: Immuno-
logical treatment of autoimmune diseases. Adv Immunol 1998,
68:333–418.
2. Schulze-Koops H, Lipsky PE: Anti-CD4 monoclonal antibody
therapy in human autoimmune diseases. In Current Directions in
Autoimmunity. Edited by Theofilopoulos A and Fathman CG. Basel:
Karger Press; 1999:in press.
3. Shizuru JA, Alters SE, Fathman CG: Anti-CD4 monoclonal antibod-
ies in therapy: creation of nonclassical tolerance in the adult.
Immunol Rev 1992, 129:105–130.
4. Horneff G, Burmester GR, Emrich F, and Kalden JR: Treatment of
rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthri-
tis Rheum 1991, 34: 129–140.
5. van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, and
Breedveld FC: A randomized, double-blind, placebo-controlled
study of CD4 monoclonal antibody therapy in early rheumatoid
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6. Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, and Lipsky
PE: Reduction of Th1 cell activity in the peripheral circulation of
patients with rheumatoid arthritis after treatment with a non-
depleting humanized monoclonal antibody to CD4. J Rheumatol
1998,  25: 2065–2076.
7. Wendling D, Racadot E, Toussirot E, and Wijdenes J: Combination
therapy of anti-CD4 and anti-IL-6 monoclonal antibodies in a case
of severe spondylarthropathy. Br J Rheumatol 1998, 35:1330.
8. Yin DP, Sankary HN, Chong AS, Blinder L, Ma LL, Williams JW: Effect
of anti-CD4 monoclonal antibody combined with human CTLA4Ig
on the survival of hamster liver and heart xenografts in Lewis rats.
Transplantation 1997, 64:317–321.
The Role of TNFa a in the Pathogenesis of Rheumatoid
Synovitis
Ravinder N Maini, Peter C Taylor, Ewa Paleolog,
Peter Charles, Sundeept Ballara, Fionula Brennan,
and Marc Feldmann
Kennedy Institute of Rheumatology, London, United Kingdom
In this presentation we summarise the insights that have been
gained into the role of TNFa in the pathophysiology of
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22rheumatoid synovitis from observations in patients receiving
infliximab (Remicade™), an anti-TNFa specific, neutralising,
monoclonal antibody [1–3].
Serial synovial biopsies and serum samples before and after
anti-TNF therapy show a reduction in the density of infiltrating
lymphocytes and macrophages associated with a reduction in
the expression of adhesion molecules E-selectin, ICAM-1 and
VCAM-1 [4]. Circulating lymphocyte count is increased in a
dose-dependent manner. Further studies have shown a
reduction in chemokine expression [5]. Taken together these
data have suggested that anti-TNF therapy alters leukocyte
trafficking patterns with a net reduction in immune and
inflammatory cell mass in the synovium.
Direct evidence of reduced retention of indium111-labelled
polymorphonuclear cells in RA joints has recently been
obtained following infliximab therapy [6]. This is likely to be due
to effects on cell margination and migration but may also reflect
a reduction in angiogenesis, a conclusion supported by the
finding of a reduction in circulating VEGF concentrations and
vessel density in serial synovial biopsies [7].
Neoangiogenesis not only increases delivery of inflammatory
cells to the joint, but plays a part in cartilage and bone
destruction in RA. It is not yet known whether anti-TNF
treatment prevents structural damage but reduced serum levels
of complexed (inactive) MMP-1 and MMP-3 are observed in
treated patients [8].
Clinical trials have demonstrated that ~30% of patients do not
appear to respond to anti-TNF therapy. Clearly other molecular
mechanisms are involved in this sub-population. In the majority
of RA patients, however, TNFa plays a key role in the
expression of synovitis. The need for continuing therapy to
control disease expression implies that other, as yet
unidentified, factors are involved in maintaining the chronicity of
disease.
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Etanercept for Treating Rheumatoid Arthritis
Larry W Moreland
University of Alabama at Birmingham, USA
Etanercept (Enbrel™) has specifically been developed to
achieve therapeutic neutralization of TNF. DNA encoding the
soluble portion of the human p75 TNFR was linked to DNA
encoding the Fc portion of the human IgG molecules and
expressed in a mammalian cell line. The resultant protein binds
two TNF molecules and has increased circulating half-life due
to the Fc moiety. In the first placebo-controlled trial, 75% of
patients receiving the highest dose of etanercept (16 mg/m2
subcutaneously twice a week) achieved at least a 20% ACR
clinical response after 3 months of therapy. This improvement
was associated with significant reductions in pain and morning
stiffness, as well as in the biochemical markers (ESR and CRP)
of disease activity. In a subsequent placebo-controlled phase III
study, using a dosing schedule of 10mg or 25mg of
etanercept subcutaneously biweekly, sustained clinical efficacy
and safety were both verified over a period of 3 months. The
25-mg dose proved superior to the 10-mg dose in terms of
effectiveness. No adverse events other than injection site
reactions were more commonly noted with either dosage
compared to the placebo group. Rheumatoid arthritis (RA)
patients with suboptimal clinical responses on DMARD therapy
may be the most optimal candidates for the addition of the TNF
antagonist etanercept to the treatment regimen. Results of a
phase II/III study of combination therapy with etanercept and
methotrexate in RA patients refractory to moderate doses of
methotrexate have recently been reported. The combination of
etanercept and methotrexate resulted in 71% of patients
achieving a 20% ACR response, compared with only 27% of
patients who received methotrexate alone. The encouraging
clinical results observed in short-term trials using etanercept
clearly warrant further studies to determine whether TNF
inhibitors are capable of modifying the destructive component
of the disease and to assess safety in long-term use. A pivotal
trial with etanercept is now in progress comparing etanercept
with methotrexate in early RA. Radiographic changes will be
measured in this trial.
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Stem Cell Transplantation in the Treatment of Rheumatoid
Arthritis and Other Autoimmune Diseases
Alan Tyndall
Rheumatologische Universitätklinik, Basel, Switzerland
The concept of hematoimmunoablation followed by autologous
hemopoietic stem cell transplantation (HSCT) as a treatment for
severe autoimmune disease has gained momentum in the past
several years. Almost from the beginning, international
consensus was reached concerning principles of patient
selection and treatment regimens, and several phase-I and -II
pilot studies were commenced. It was also agreed to collect as
much data as possible following mobilisation in order to develop
a databased risk assessment of the procedure and later to
balance this against benefit. Under the auspices of the EBMT
and EULAR, a database was established, which was later
extended to include Australian and US cases. The current
database includes over 150 cases and has been presented in
several forums. In addition, the IBMTR contains similar cases and
case reports, and small series have been published. The majority
of cases have been MS, followed by scleroderma (systemic
sclerosis or SSc), RA, juvenile arthritis, SLE, and others.
A preliminary analysis of the international data base showed a
transplant-related mortality of 9%, comparable to that seen in a
group of lymphoma patients treated in the EBMT centres over
the same period (6%). So far, no fatalities have been published
in the literature.
Several issues have emerged as the experience grows. The
most important is patient selection and exclusion. The original
loose guidelines of ‘potentially sick enough to justify the risk
but not too severe to be either irreversible or too ill for the
treatment’ have proven difficult to quantify. Potential disease-
specific aspects contribute to transplant-related mortality (eg
cardiac involvement in SSc and cyclophosphamide toxicity)
and to transplant-related problems (eg age of patient and
general medical condition). The unwanted events have been
generally consistent with previous BMT experience, with the
possible exception of mobilisation complications in SSc.
Several subgroups have been formed under the auspices of
the EBMT to look at disease-specific aspects in SSc,
RAS/JCA, MS, and SLE/vasculitis, and these findings will be
published.
Concerning mobilisation-related events, a suggestion of growth
factor-related autoimmune disease (AD) flare is subject to a
separate ongoing study. The current feeling is that in
systematically active AD, such as Still’s disease, SLE, and
vasculitis, cyclophosphamide should be given prior to growth
factor until more data are available. Only a few patients have
experienced failed mobilisation, and this was successful at
second mobilisation in most.
No conditioning regimen has so far proven superior with
respect to remission induction and/or maintenance. Regimens
have mostly followed published guidelines, with a suggestion
of more infectious complications following heavy T-cell purging.
Efficacy has ranged from dramatic to none and death from
disease progression. In general, outcome measurement has not
been standardised between groups but is well defined within
the individual centres. Around two thirds have been reported as
‘improved or stabilized,’ and more data are required, including
relapse rates and severity.
Data collection is critical, with a current liaison group working
toward standardising MED A and MED B equivalent data
collection in Europe and the US. In particular, standardised
measurements of immune or B-cell phenotype in peripheral
blood has been associated with successful or unsuccessful
outcome. As predicted, heavy T-cell purging was associated
with more prolonged T-cell CD4-penia and increased infection.
This is also subject to a subgroup working party. Eventually, the
final place of such a treatment, if it exists, will be established
through prospective comparative trials.
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